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ABSTRACT
The rate of successful treatment for Helicobacter pylori infections, with the
clarithromycin triple therapy, is only 75%. The triple therapy, which consists of a proton
pump inhibitor and two broad-spectrum antibiotics such as clarithromycin and
amoxicillin, is becoming less effective due to the rise of strains with resistance against
these antibiotics. In the search for narrow spectrum drugs for the treatment of H. pylori
infections, a high-throughput screen was performed to identify selective compounds
against H. pylori. This screen revealed two selective and structurally related
thienopyrimidines. Structure-activity relationship of the thienopyrimidines against H.
pylori was examined through the synthesis of 27 analogs, efforts that merged elements of
the two scaffolds. The resulting leads, including compound 25, demonstrate high potency
with an acceptable cytotoxicity profile against the human FaDu cells. Mode of action
studies were performed by the generation and sequencing of resistant mutants. These
experiments identified H. pylori’s respiratory Complex I as the putative target of the
series, with the amino acid changes found in the NuoD subunit. Lead compounds
demonstrated efficacy in an ex vivo model but not in the in vivo studies in a H. pylori
murine infection model, suggesting further optimization of the pharmacological
properties is required for this series. A scaffold hopping exercise was performed to
discover novel scaffolds with improved ADME properties. The pyrrolopyrimidine 56
emerged with good anti-H. pylori activity, an improved solubility and is less bound to
human plasma protein. Lead optimization efforts are ongoing, to realize proof of concept
of this series of compounds in the in vivo efficacy studies.
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CHAPTER 1.

INTRODUCTION

H. pylori Infections and Diseases
Helicobacter pylori infects more than 50% of the world’s population.1,2 In the
United States, more than 500 000 cases of H. pylori infections are diagnosed annually,
according to the Center for Disease Control and Prevention.3 The majority H. pylori
infections leads to gastritis, often without showing symptoms.1,4 10% of the H. pylori
infections lead to peptic ulcers.5 Peptic ulcers are often chronic and may cause bleeding,
perforation and eventually death.4 Less commonly, H. pylori infections may result into
certain forms of cancer such as mucosa-associated lymphoid tissue (MALT) lymphoma,
gastric and pancreatic adenocarcinoma.6 The World Health Organization (WHO) lists H.
pylori as a class I carcinogen.7 Often, acute gastritis becomes chronic and then chronic
gastritis leads to metaplasia and adenocarcinoma.4 Gastric cancer is the fourth most
common cancer and the second leading cause of deaths among all cancers.8 H. pylori has
also been implicated in the pathogenesis of many other diseases including idiopathic
thrombocytopenia purpura, idiopathic iron deficiency anemia, ischaemic heart diseases,
ischaemic cerebrovascular disease, atherosclerosis, Raynaud’s phenomenon and many
skin diseases.4
Barry Marshall and Robin Warren were awarded the Nobel Prize in 2005, for
their work that established H. pylori as the causative agent of gastritis and peptic ulcers. 9
Their discovery enlightened the long-standing ambiguity around the cause of peptic
ulcers. As result, patients with peptic ulcers and gastric cancer are recommended to be
tested for H. pylori infections.10 The tests that are conducted to identify active infection
include the urea breath test, fecal antigen test and mucosal biopsy-based testing that relies
on endoscopy.11 H. pylori is generally identified in 70% of antral biopsy specimen of
patients with chronic gastritis and 90% of patients with duodenal ulcers.4 The eradication
of H. pylori is recommended in treating gastritis, instead of drugs that suppress the high
gastric acidity.12,13,14 Patients treated by eradicating the bacteria show lower relapse rate
(9%) without recurrence, as oppose to high relapse rates (58-67%) identified with
patients who manifest the infection after treatment.4 H. pylori eradication is also
recommended in both treating low grade MALT lymphoma and preventing gastric
cancer.15-17 According to a study that was conducted in Japan, nearly 80% of 420 patients
who tested positive for the gastric MALT lymphoma, responded to the eradication
therapy with minimal residual disease.18 Usually, the eradication of H. pylori is
confirmed using the tests, mentioned above.11
The Treatment Against H. pylori Infections
The clarithromycin triple therapy consists of a Proton Pump Inhibitor (PPI),
clarithromycin and either amoxicillin or metronidazole for 14 days. (Figure 1-1) In the
2017 American College of Gastroenterology (ACG) guidelines, the clarithromycin triple
therapy is recommended as the first-line treatment for H. pylori infections.11 However,
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Figure 1-1. Anti-H. pylori drugs.
(A) Structure of clarithromycin. (B) Structure of amoxicillin. (C) Structure of
metronidazole. (D) Structure of levofloxacin. (E) Structure of ciprofloxacin. (F) Structure
of rifabutin.
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the clarithromycin triple therapy have shown limitations. The clarithromycin triple
therapy has been associated with lower eradication rates, when it is administered for a
shorter period of 7 to 10 days. The drug, clarithromycin is highly recommended as a first
line treatment for patients who have not been previously exposed to macrolides and who
are in the area identified with low resistance against clarithromycin (< 15%).19
Clarithromycin is a bacterial static agent that acts following the inhibition of protein
synthesis via binding to the 50S ribosomal subunit. Amoxicillin is a bactericidal agent
and inhibits the synthesis of the cell wall. These antibiotics act on actively replicating
bacteria. 20 A proton pump inhibitor such as omeprazole, acts by suppressing the secretion
of gastric acid, which allow the bacteria to replicate and facilitate the bactericidal effects
of the antibiotics.
A strong association has been reported between the number of previous exposures
and a high risk of antibiotic resistance.21 In general, the appropriate regimen for the
treatment against H. pylori infections is recommended based on the drug resistance
pattern in the region and the patient’s exposure to the antibiotics and the patient
compliance.22 For patients who have an allergy to penicillin, amoxicillin is substituted
with metronidazole in the clarithromycin triple therapy regimen. The use of either
metronidazole or amoxicillin achieves the same therapeutic effect.23 Inside the bacteria,
metronidazole is metabolized by nitroreductase enzymes into metabolites that are toxic to
bacteria. The triple therapy regimen, containing metronidazole, is recommended to
patients who have been previously exposed to macrolides.
The bismuth quadruple therapy is another recommended first-line treatment,
which consists of a PPI, bismuth, a tetracycline and a nitroimidazole for 10-14 days.11
(Figure 1-1) In case the clarithromycin triple therapy fails to eradicate the infection, the
bismuth quadruple therapy is recommended as a salvage treatment. The use of bismuth as
part of the regimen achieves the eradication rate of above 90%.24 However, the role of
bismuth is not well understood. Marcus et al. suggests that bismuth hinders proton entry
into the bacteria which leads to the up-regulation of growth depended genes and H. pylori
becomes more susceptible to the antibiotics.25
The concomitant, the sequential, the hybrid and the fluoroquinolone sequential
therapies are other first line treatment options that are used worldwide for the treatment
of H. pylori infection. The concomitant therapy consists of a PPI, clarithromycin,
amoxicillin and a nitroimidazole for 10 to 14 days.11The sequential therapy consists of a
PPI and amoxicillin for 5 to 7 days followed by a PPI, amoxicillin, clarithromycin and a
nitroimidazole for 5 to 7 days. The hybrid therapy consists of a PPI and amoxicillin for 7
days followed by a PPI, amoxicillin, clarithromycin and a nitroimidazole for 7 days.
Fluoroquinolone sequential therapy consists of a PPI and amoxicillin for 5-7 days
followed by a PPI, fluoroquinolone and nitroimidazole for 5-7 days with levofloxacin and
ciprofloxacin as the fluoroquinolone drugs. (Figure 1-1) The concomitant, the sequential
and the hybrid therapies have been found to achieve the same efficacy based on clinical
research data published by ACG.11 According to the recent meta-analysis, the sequential
and concomitant therapies have shown higher eradication rates (>90%), than the
clarithromycin triple therapy (>70%).10The concomitant therapy, in particular, is
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preferred among these alternative first-line therapies, given it constitutes a simpler
regimen that affords patient compliance.
The levofloxacin triple therapy, the rifabutin triple therapy and the high-dose dual
therapy are recommended as salvage treatments, in case the first line treatment fails to
eradicate the infections. (Figure 1-1) The levofloxacin triple therapy, which consists of a
Proton Pump Inhibitor (PPI), levofloxacin and amoxicillin for 10 to 14 days, is
recommended as a salvage regimen, in case the clarithromycin triple therapy or the
bismuth quadruple therapy fails to eradicate H. pylori. Rifabutin triple regimen consists
of a PPI, amoxicillin and rifabutin for 10 days. High-dose dual therapy consists of a PPI
and amoxicillin administered for 14 days. Despite the availability of these alternative
regimens, the rate of successful treatments has significantly declined worldwide, due to
the rise of resistance against the antibiotic components of these regimens.1,26
The Resistance Against Anti-H. pylori Drugs
H. pylori has become a global threat due to a steady increase of worldwide drug
resistance against anti-H. pylori drugs. H. pylori is listed as a high priority drug-resistant
bacterium by the World Health Organization among bacteria that are threat to the human
health.7 Worth noting, the rate of successful treatment of H. pylori infections has dropped
below 80%.1,26 In a recent study, 22% of patients tested in a clinical trial were not cured
by either the triple therapy or the quadruple therapy.27 In the early 1990s, the worldwide
treatment rate of H. pylori infections with the triple therapy were recorded at 80-90%.28
From 1998 to 2002, the United States national sampling study reported a resistance rate
of 21% against metronidazole and 13% against clarithromycin.29 Between the year of
2000 and 2008, the resistance rate in Alaska was recorded at 42% and 30% against
metronidazole and clarithromycin respectively.30 In 2012, the resistance rates were
reported at 20% and 16% by the Houston VA medical center, for metronidazole and
clarithromycin respectively.31 In particular, the resistance against metronidazole has been
fueled by its overuse in the regions predominated by parasitic diseases.19 In certain parts
of the world, such as Japan, the resistance rate against metronidazole is low, due to its
restricted use at the national level.32
The effectiveness of the regimens for the treatment of H. pylori infection, has
declined due to the resistance against the antibiotics at various degrees. The metaanalysis studies have revealed that the resistance against clarithromycin is the major
contributor to the failure of the triple therapy.10 More worrisome, the fluoroquinolone
resistance has been recorded as high as clarithromycin resistance (rate: 16%), in North
America.31,33 Although in vitro resistance against metronidazole (rate: 20%) is high
worldwide, H. pylori mutations against clarithromycin or levofloxacin are the most
clinically relevant mutations. They are usually identified using molecular methods
including polymerase chain reaction or fluorescently-labeled nucleic acid hybridization.
These methods have been optimized overtime and are simply applied to clinical isolates
collected from gastric mucosal biopsies or fecal samples.34 The resistance against
amoxicillin, tetracycline and rifabutin are still low (rate: < 2% for each), whereas the
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resistance against bismuth hasn’t been reported worldwide.11,35 The resistance rates
against these antibiotics are registered higher in children than adults, because the same
drugs are prescribed for the treatment of diseases that are prevalent in children, such as
the respiratory and parasitic diseases.36 Clarithromycin, fluoroquinolones and rifabutin
are generally discouraged to be reused in the clinic, given the resistance against these
drugs cannot be overcome by simply increasing the dose.
Point mutations have been the primarily mechanism of resistance against the
antibiotics for the treatment of H. pylori infections. In H. pylori, point mutation in the
23S rRNA are the main mechanism of resistance against clarithromycin. Mutations in the
penicillin binding proteins drive the resistance against amoxicillin. The resistance against
levofloxacin comes from the mutation in the gyrA gene, which encodes the subunit A of
DNA gyrase.38Various mechanisms have been reported as the basis for the resistance
against metronidazole.
The resistance against metronidazole originate from the mutations in the rdxA
gene. In bacteria, rdxA encodes for NADPH nitroreductase, which is responsible for
activating metronidazole and other nitroaromatic compounds into toxic metabolites.39
The efflux pump, hefA is found overexpressed in resistant H. pylori strains and has been
reported to play a key role in reducing the cellular concentrations of metronidazole.40
hefC, a multidrug efflux pump, also reduces drug concentrations to below effective
concentrations.41
The side effects from the use combination broad spectrum antibiotics, contributes
to poor patient compliance affecting the success of these treatments.10 The use of these
broad-spectrum antibiotics perturbs the gut microbiome, leading to symptoms like
diarrhea.11 Other side effects associated with the triple therapy include: headache,
dizziness, nausea, dysgeusia, dyspepsia, pseudomembranous colitis, mycosis, sore mouth
and tongue, drug hypersensitivity and paraesthesia. Given the rise of resistance, specific
therapies against H. pylori infections are needed to preserve these broad- spectrum drugs,
that are crucial for the treatment of other infections and to mitigate the side effects
associated with these drugs.
H. pylori’s Colonization and Virulence
H. pylori is a spiral gram-negative bacterium that colonizes in the human
stomach.42 H. pylori infections are generally acquired at a young age via oral-oral
route.43,44,45 Given H. pylori can only survive for 30 minutes, H. pylori must move
quickly to avoid gastric emptying and penetrate the stomach mucus layer.46 H. pylori is
found in the corpus and the antrum regions of the stomach, which differ in their cellular
make up.47 H. pylori colonizes areas in close association to the epithelial cells, to form a
niche where it releases cytotoxins.48 Although, the majority of bacteria are found freely
swimming in the lumen, important populations of H. pylori are also found beneath the
gastric mucous layer and within the glands, regions that are considered more favorable
environment for long term survival than the lumen (pH < 2).
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The pH gradient of different regions of the stomach is a major factor in
determining H. pylori’s colonization site.46 H. pylori is a bioenergetically neutrophil, with
the ability to survive in an environment with a pH range of 4-8.49 Unlike other bacteria,
H. pylori can inhabit acidic milieu, by maintaining a favorable pH in the proximity via 2
proteins: the urease which hydrolyzes urea into CO2 and ammonia, and the α-carbonic
anhydrase protein, which catalyzes the conversion of CO2 to HCO3- and eventually
reduces the concentrations of HCl.50-52 UreI is the proton gated channel, responsible for
the urea influx. The protein urease is also found at the surface layer of the cell. The
ammonia reacts with HCl to create a neutral surrounding environment in the periplasm
and around the bacterium. The diffusion rate of chemicals, including ammonia, is
significantly diminished in the mucus, which allows the acid to be neutralized and the
neutral pH is maintained for a long period.53
H. pylori reaches the epithelial cells at the surface of the stomach, by motility
with the flagella and the chemotaxis signaling system.54 Recent studies have shown that
the wildtype strains swim faster in viscous environment than the mutants with straight
cell bodies, suggesting H. pylori’s spiral shape facilitate the bacteria to penetrate the
mucus, in addition to the flagella.55, 56 The bacterium utilizes chemotaxis, a mechanism
that allows H. pylori to measure the concentration of the attractant and repellent
substances, to flee undesirable conditions for growth. With chemotaxis, H. pylori can
detect urea, metals and amino acids in the environment.57-59 It can detect injured
epithelial cells that supply high concentrations of nutrients in the environment.60 The
antrum and the corpus are populated with differentiated cells, with variation in
concentrations of nutrients and metabolites such as sugars and amino acids. H. pylori’s
chemoreceptors, known as transducer like proteins, TlpA, TlpB, TlpC and TlpD, play an
important role of inputting environment signals that the bacterium utilizes to determine
the swimming direction toward a favorable environment to grow and colonize.61 For
instance, H. pylori’s TlpA senses its attractant, arginine, and in response the bacterium
swims toward the source of this essential amino acid.62 TlpB senses a repellent, autoinducer 2 (AI-2), that allows H. pylori to determine the density of other bacteria in the
surrounding area as it grows and colonizes in the stomach.63
H. pylori produces two main cytotoxins: the cytotoxic associated gene (CagA)
and the vacuolating cytotoxin (VacA).64,65 H. pylori adheres to the epithelial cells using
adhesion factors to deliver CagA.66,67 Type IV secretion system (T4SS) delivers CagA
upon attachment to the epithelial cells. Inside the human cells, CagA triggers the
alteration of transduction signals and gene expression.68-70As a result, different signaling
pathways are affected, including pathways that participate in cell-cell tight junction and
pro-inflammatory response. Upon interaction with the host cell, T4SS alone can trigger
pro- inflammatory response and the production of the chemokine IL-8.71 Unlike CagA,
H. pylori actively secretes VacA not requiring adhesion which interacts with the plasma
membrane of host cells, leading to the formation of anion channels, Cl-ions influx and the
formation of vacuoles.72 Inside the host cell, VacA leads to the release of proinflammatory proteins and the induction of apoptosis.73,74 H. pylori benefits from
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apoptosis of the host cells, which results in an increase of nutrients in the surrounding
environment or diminished immunity that comes with the degradation of immune cells.75
The Status of Discovery of the Anti-H. pylori Drugs
H. pylori Genome and Target-based Drug Discovery
Advances in whole genome sequencing have provided opportunities for targetbased drug discovery against H. pylori. Targeting the genes that promotes the growth and
colonization of H. pylori is a promising strategy in the discovery of new therapies against
H. pylori infections. In 1997, the complete genome sequence of the H. pylori 26695 strain
became available.77 A couple of years later, the genome of H. pylori J99 strain was
reported.78 The analysis of these genomes revealed that 60% of the genes produce
proteins of known function based on the sequence similarity to their orthologs that are
found in the public database.79 23% of the remaining genes have their corresponding
orthologs in the public domain, however the function of their gene products is unknown.
The rest of the genes (17%) have not been matched in the public database and the
function of these genes have yet to be determined.
A recent transposon mutagenesis study identified 344 H. pylori essential genes. 80
The function of 24% of these H. pylori specific genes remains unknown. Some of these
unique H. pylori genes are believed to enable H. pylori, to grow under the gastric
mucosa, in close association with the epithelial cells.81 Other studies have discovered
genes responsible for the motility of H. pylori, a function that facilitates H. pylori to
penetrate and colonize in the mucus.82 Other genes have been associated with
chemotaxis, a mechanism that enables H. pylori to survive the gastric acidity.83,84 More
genes have identified by the knock out mutagenesis to be involved in different cellular
functions such as cell envelope synthesis, cell division, protein synthesis, gene expression
and regulation, cell metabolism and energetics.79 The existence of these H. pylori specific
genes suggest that H. pylori possesses unique proteins that can be targeted for the
treatment of H. pylori.
Phenotypic/Highthrough-put Screening for Anti-H. pylori Drugs
The existence of many unique genes provides opportunities to selectively target
H. pylori. The highthrough-put screen of compound library is a promising approach to
identify active compounds against H. pylori. In addition, there is a high likelihood of
finding selective hits against H. pylori by screening commercial libraries, given these
libraries are often screened to identify broad-spectrum, while narrow-spectrum
compounds are overlooked.
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Examples of Novel Anti-H. pylori Compounds
Various research groups have published compounds that have demonstrated
activity and selectivity against H. pylori. Katsura et al. published a series of guanidino
analogs that demonstrates selectivity comparable to the standard of care drugs such as
metronidazole and amoxicillin. 85-89 The structure activity relationship of the guanidino
compounds focused on the guanidine substitution and the 4 position of the thiazole
ring.86,88-90 Among these guanidino analogs, compound 6 (Figure 1-2A) demonstrates the
highest potency with an MIC of 0.17 ug/mL.85 Ando et. al reported a series of
arylacetamides analogs that were discovered through compound screening efforts.91 The
lead compound, structure shown in Figure 1-2G, demonstrates high potency (MIC = 0.39
μg/mL), selectivity and stability in acidic conditions. The pyrazole derivatives have
demonstrated activity and selectivity against H. pylori (Figure 1-2H) demonstrates good
potency (MIC = 0.125 μg/mL) and selectivity against H. pylori. 92-94 Dihydroorotate
dehydrogenase (DHOase) was reported as the target of the pyrazole lead compound (MIC
= 0.125 μg/mL, Figure 1-2H), a key enzyme in the de novo biosynthesis of pyrimidines.
Other natural product compounds have demonstrated activity and selectivity against H.
pylori, including the pyloricidins (A, B and C), the phthalide derivatives, the pyrone
derivatives, Indolmycin and Calvatic acid. 95-104 These compounds, structures shown in
Figure 1-2B, C, D, E and F, have demonstrated potency with a MIC equivalent to 0.006
μg/mL, 5ng/mL and 0.003 μg/mL, 0.016 μg/mL and 0.016 μg/mL respectively.
The Benzimidazole Series
Researchers at AstraZeneca discovered a series of benzimidazole analogs
including lead compound in Figure 1-2I with a high potency (MICs <0.5 ug/mL) and
selectivity against diverse H. pylori strains.105 In this study, resistant H. pylori mutants
were generated with the lead compound of the series (Figure 1-2I). 106 The genomic
DNA of the mutants were isolated and transformed into a sensitive strain (AH244),
confirming that these DNAs can confer resistance. The genomic library of the mutant was
constructed and mapped onto the H. pylori strain J99 genome to identify resistant genes.
This study revealed a single point mutation in nuoD (NADH:Quinone oxidoreductase)
that yielded the amino acid change G398S. NuoD was confirmed as the putative target,
with the additional 32 independent spontaneous mutants that revealed missense mutations
which resulted in the amino acid changes: G398S, F404S and V407M. NuoD is one of
the polypeptides that make up H. pylori’s respiratory Complex I, a proton-pumping
oxidoreductase that is located in the plasma membrane. 107 It catalyzes the first step of
oxidative phosphorylation, by transferring 2 electrons from NADH to quinone.
According to this study, the benzimidazoles bind at the interface of NuoD and the
neighboring subunit NuoB. H. pylori’s complex I and E. coli’s complex I were sensitive
to rotenone, an inhibitor of Rhodobacter capsulatus’ complex I inhibitor, whereas the E.
coli’s complex I was not sensitive to the benzimidazole lead (Figure 1-2I), suggesting
that the benzimidazoles are selective against H. pylori.108 Knockout mutagenesis
experiments determined that nuoD was essential for the viability of H. pylori strain J99
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Figure 1-2. Structures of published anti-H. pylori compounds.
(A) Guanidinothiazole derivative (MIC = 0.17 μg/mL). (B) Pyloricidin derivative (MIC <
0.006 μg/mL). (C) Phthalide derivative (MIC = 5.00 ng/mL). (D) Pyrone derivative (MIC
= 0.003 μg/mL). (E) Indolmycin (MIC = 0.016 μg/mL). (F) Calvatic acid (MIC = 0.016
μg/mL). (G) Arylacetamide derivative (MIC = 0.39 μg/mL). (H) Pyrazole derivative
(MIC = 0.125 μg/mL). (I) Benzimidazole derivative ( MIC < 0.5 μg/mL). (J) HPi1 ( MIC
< 0.16 μg/mL).
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and AH244. In E. coli, nuoD and nuoC genes are found fused and they encode a single
polypeptide.109 In H. pylori, these genes are separated, emphasizing the essentiality of
nuoD in H. pylori, and not for other bacteria including E. coli.
The Discovery of Hpi1
Recently, we conducted a highthrough-put screen of 30,000 compounds to
identify selective compounds with activity against H. pylori.81 The conditions for growing
H. pylori were optimized in a 384 well plate, a challenging foot given the requirement of
H. pylori for microaerophilic growth conditions. Promiscuous compounds were identified
and eliminated studying the activity against a panel of commensal bacteria.
Bacterial growth was measured by reading the reduction of resazurin (blue dye), a
metabolic indicator, to resorufin (pink fluorescent compound). The screen yielded HPi1
(Figure 1-2J), a selective hit compound, which demonstrates a high in vitro potency
(IC50 of 0.24 μM) compared to Clarithromycin (0.04 μM) and good selectivity against a
panel of commensal bacteria such as Lactobacillus casei, Lactobacillus reuteri and
Bifidocterium longum. In the in vivo studies, HPi1 showed efficacy when tested in the H.
pylori murine model at 25 mg/kg (p.o.). Hpi1 reduces the colony counts to below the
limit of detection. Attempts to generate resistant mutants against HPi1, by serial passage
on agar plate or from Hpi1 treated mice, were not successful and its target is unknown.53
Repurposing Other Antibiotics for the Treatment of H. pylori
Fluoroquinolone compounds have been explored for the eradication of H. pylori.
Finafloxacin, a novel fluoroquinolone, demonstrates superior anti-H.pylori activity in
acidic conditions than other fluoroquinolones.110 Sitafloxacin, a fluoroquinolone
antibiotic, show higher anti-H. pylori activity (MIC90: 0.06 μg/mL) than metronidazole,
clarithromycin, amoxicillin, tetracycline, doxycycline, minocycline, norfloxacin,
ciprofloxacin and levofloxacin against 293 H. pylori strains, with low resistance
development.111 In combination with lansoprazole, sitafloxacin eradicates H. pylori in
vivo at 83.3% rate. At 1 mg/kg, the Cmax of sitafloxacin is 10 fold higher than its MIC.
DX-619, a des-F(6)-quinolone, is active against gram-positive bacteria including MRSA
and vancomycin resistant enterococci.112 DX-619 also demonstrates bactericidal activity
against 293 H. pylori strains, including those that are resistant to metronidazole,
clarithromycin, amoxicillin and levofloxacin, with MIC50 of 0.008 mg/L and MIC90 of
0.06 mg/L.
Some macrolides have been reported to show anti-H. pylori activity.
Azithromycin, a macrolide antibiotic, demonstrates an in vitro MIC90 of 0.25 mg/L.113
Azithromycin is stable in acidic conditions and exhibits physical chemical properties that
allows a rapid migration of drug from blood to tissue and a slow release from tissue to
blood circulation. The evaluation of in vivo pharmacokinetic properties revealed that the
concentration of Azithromycin in mucosa was significantly higher than in plasma,
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ranging between 18.5 mg/kg and 24.6 mg/kg after a single oral administration (2.3-4.6
mg/kg). After 30 days of treatment with azithromycin at 500 mg/kg (+ omeprazole at 40
mg/kg), eradication of H. pylori was achieved in 80% of patients. Dirithromycin and
roxithromycin demonstrates anti-H. pylori activity with MIC50 of 0.25 and <0.008
μg/mL, respectively.114 These macrolides show acid stability unlike other macrolides
such as erythromycin, ethylsuccinate, josamycin and spiramycin.
Marketed drugs to treat infections caused by parasites, have also investigated for
growth inhibition of H. pylori. Artemisinin and its derivatives have been explored for
their anti-H. pylori activity.115 Five artemisinin derivatives, b-artecyclopropylmether, barteether, a-arteether, b-artemether and b-artefurfurylether, show anti-H. pylori activity
and lack activity against the majority of other bacterial and fungal strains. Bartecyclopropylmether is the most active with MIC of 0.25-1 μg/mL at the stomach pH.
B-artecyclopropylmether demonstrates mild in vivo efficacy at 50 mg/kg/day as a single
therapy. The mechanism of action of the artemisinin derivatives is not well understood.
Nitazoxanide (NTZ), a thiazolide drug, is a broad-spectrum drug used for the treatment of
infections caused by parasites and helminths.116 NTZ exhibits activity against H. pylori
and is a non-competitive inhibitor of pyruvate:ferredoxin/flavodoxin oxidoreductase
(PFOR) of H. pylori. PFOR catalyzes the oxidative decarboxylation of pyruvate to acetyl
CoA and CO2. It is only found in anaerobic bacteria, anaerobic parasites and epsilon
proteobacteria.
Drugs targeting proton pump enzymes have demonstrated anti-H. pylori activity.
Rabeprazole and its thioether derivative inhibits the motility of H. pylori with inhibition
of 50% of motility at 16 and 0.25 μg/mL respectively.117 The inhibition of motility is
observed instantly when bacteria is exposed to the agent, but growth inhibition is realized
after hours of incubation. Lansoprazole, a benzimidazole proton pump inhibitor, show
high activity against H. pylori with MIC of 3.13-12.5 μg/mL.118Under acidic conditions,
lansoprazole is transformed into AG-2000 and AG-1812, which show comparable
activity to lansoprazole. These compounds lead to morphological change of cell, their
constriction, collapse of cell surface structures and eventually cell death. Lansoprazole
and its metabolites (AG-2000 and AG-1812) do not show activity at 100 μg/mL against
aerobic, anaerobic bacteria and campylobacter jejuni. Lansoprazole is found highly
distributed in the gastric mucosa and less in the serum. Idebenone and other quinones
including duroquinone, menadione, juglone and coenzyme q1 inhibit H. pylori growth at
the MIC90 of 1.6-3.2 μg/mL.119 Idebenone inhibits respiration and triggers the reduction
of the cellular ATP level, without showing adverse effect to human cells. Idebenone is
selective against H. pylori and does not show activity against a variety of bacteria
including Bacillus subtilis, Staphylococcus aureaus, Streptococcus salivarius and
Pseudomonas aeruginosa.
Other antibiotics and non-antibiotics have shown anti-H. pylori activity. Blactams including cefuroxime, cefetamet, ceftetrame, cefixime and tigemonam,
demonstrate activity against H. pylori with MIC50 of 0.125, 2, 0.5, 0.06 and 0.25 μg/mL,
respectively. 114 The antimycotic ketoconazole is active against forty H. pylori strains at
MIC50 and MIC90 of 16 and 32 mg/L respectively.120 Mupirocin, a topical antimicrobial
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for the treatment of staphylococcal infection of the skin, show activity against 57 strains
of H. pylori with MIC90 of 0.25 and 0.12 mg/L at pH 7.4 and 5.4 respectively.121
Linezolid, an oxazolidone indicated for staphylococcal and streptococcal infections, has
demonstrated activity against gram-negative bacteria.122 Linezolid in
hibits 70
strains of H. pylori at the MIC50 of 8-64 μg/mL. Simethicone, a non-antibiotic and antifoaming agent used to treat meteorism, demonstrates anti-H. pylori activity with an MIC
of 64-128 mg/L.123 HSR-903, a quinolone compound, demonstrates anti-H. pylori activity
with MIC50 of 0.20 μg/mL and MIC90 of 12.5 μg/mL.124
Research Goals
In conclusion, new therapies for the treatment of H. pylori infections are needed,
given the rise of resistance against current antibiotics. The development of narrow
spectrum anti-H. pylori drugs should be prioritized to reduce side effects from disruption
of the microbiome. Advances in whole genome sequencing have revealed many H. pylori
targets for the discovery of selective anti-H. pylori compounds. The highthrough-put
screen of commercial libraries is an attractive approach in the discovery of selective
compounds against H. pylori. However, lead optimization campaign of compounds
discovered from a phenotypic screen is more challenging and takes a long time compared
to compounds that are developed through target-based drug discovery approach. The
generation of mutants and genome sequencing techniques enable the study of mode of
action of novel antimicrobials. To eradicate H. pylori in vivo, compounds must
demonstrate the ability to reach the colonization site, in the mucus layer of the stomach.
The goals of the research presented in this dissertation are to identify active compounds
against H. pylori through the highthrough-put screening approach, to explore the hit
compounds through the structure-activity relationship for improved potency and to
optimize the in vitro and in vivo pharmacokinetic properties the resulting lead compounds
for proof of concept studies in H. pylori infected mice.
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CHAPTER 2. THE DISCOVERY AND DEVELOPMENT OF
THIENOPYRIMIDINES AS INHIBITORS OF HELICOBACTER PYLORI
THROUGH INHIBITION OF THE RESPIRATORY COMPLEX I
Introduction
Helicobacter pylori is a major causative agent of gastritis, peptic ulcers and
ultimately gastric cancer. According to the Center for Disease Control, more than
500,000 cases of H. pylori infections are diagnosed annually in the United States.1 The
triple therapy, consisting of a proton pump inhibitor and broad spectrum antibiotics
clarithromycin and amoxicillin, is the recommended treatment against H. pylori
infections.2 The rate of successful treatment with the triple therapy has dropped below
80% due to the rise of resistance.3-6 In a recent study, 22% of patients tested in a clinical
trial were not cured by the triple therapy.5 Additionally, the intensive use of the broadspectrum antibiotics for H. pylori infections perturbs the gut microbiome, leading to side
effects such as diarrhea and drug resistance in commensal pathogens.2 Given the rise of
H. pylori resistance, new drugs and approaches are needed for the eradication of H. pylori
infections.
A high-throughput screening protocol was developed that addressed the H. pylori
challenge of growing H. pylori in a fastidious microaerophilic environment required for
growth, to discover novel chemical matter active against H. pylori.7 Hits were then
counter-screened against Staphylococcus aureus to remove promiscuous compounds,
against gut commensal bacteria and mammalian cell lines to discover selective hits that
can eradicate H. pylori while preserving the host microbiota.7 From this approach we
have previously reported Hpi1 (Figure 2-1A), a selective anti-H. pylori compound that
emerged as a hit, with excellent in vitro potency (H. pylori IC50 of 0.24 ± 0.04 μM)
compared to clarithromycin (0.04 ± 0.01 μM) and amoxicillin (0.08 ± 0.04 μM).7 The
screening approach was subsequently applied to a larger library of 219,197 compounds.8
2,027 compounds emerged as positive hits and these compounds were clustered and
subsequently prioritized based on their solubility and their chemical tractability. To
eliminate generally toxic compounds, 511 were picked and counter-screened against S.
aureus and gut commensals including Bifidocacterium longum ATCC BAA-999,
Lactobacilus casei ATCC 334 and Lactobacillys reuteri ATXX 23272 and FaDu human
cell line to eliminate promiscuous compounds. This screen identified two
thienopyrimidine compounds, whose activity was confirmed by resynthesis and testing, 1
and 2 (Figure 2-1A), with the H. pylori IC50 values of 0.46 μg/ml and 0.59 μg/ml
respectively as prospective series leads.
Herein, we report the structure-activity relationship developed from the
optimization thienopyrimidines hits 1 and 2 against H. pylori, efforts that examine
substitutions around the thienopyrmidine core and merge elements of the two hits. Leads
are developed based on their activity and cytotoxicity profiles, and their efficacy in the in
vivo and ex vivo H. pylori infection models in mice is examined. Through resistance
generation, whole genome sequencing and resistance transfer, NuoD subunit of
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Figure 2-1. Structures of hit compounds from a highthrough-put screen against
H. pylori and SAR development of the thienopyrimidines series.
(A) Structure of Hpi1, a selective anti-H.pylori compound that emerged as a positive hit
from a high through-put screen against H. pylori. (B) and (C) Structures of
thienopyrimidines hits 1 and 2, that were identified using a similar screening approach
with the H. pylori IC50 of 0.46 μg/mL and 0.59 μg/mL respectively. (D) The StructureActivity Relationship (SAR) of the thienopyrimidines against H. pylori is reported in four
series, at the 4, 5 and 6 positions.
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Complex I was discovered as the putative target and validated by resistance transfer. A
homology model of the putative H. pylori NuoD binding site was created and the binding
mode of the leads examined. These studies produced tractable thienopyrimidine leads
with a defined mechanism of action suitable for further optimization of their ADME and
in vivo properties.
Materials and Methods
Chemical Synthesis
Starting materials were purchased from the major vendors such as Sigma-Aldrich
and Enamine. Chemical reactions were monitored by the thin-layer chromatography
(TLC) and the Waters ACQUITY-UPLC-MS-UV system. Microwave-assisted chemical
reactions were carried out in the Biotage Initiator+. The reaction mixtures were purified
using the Biotage Flash column chromatography system, with silica cartridges acquired
from Biotage Inc. The solvents for chromatography were purchased from Sigma-Aldrich.
NMR spectra were obtained using the Bruker 400 MHz NMR spectrometer and the
Bruker AVANCE 500 MHz NMR spectrometer. NMR analysis was carried out using the
MestReNova software. The chemical shifts and the coupling constants (J) are reported in
ppm and hertz (Hz) respectively. The purity of compounds was determined to be >95%
by UPLC-MS-UV system and NMR. Optical rotation of the chiral compounds was
determined using JASCO P-1010 Polarimeter.
Synthesis of Thienopyrimidine Analogs
Ethyl 2-amino-5-phenylthiophene-3-carboxylate (5). In a microwave tube, ethyl
3-cyanopropanoate 4 (1.771 mL, 16.65 mmol) was added to a solution of 2phenylacetaldehyde 3 (2 g, 16.65 mmol), sulfur (0.587 g, 18.315 mmol) and morpholine
(1.579 mL, 18.315 mmol) in ethanol (20 mL). The resulting mixture was submitted to
microwave heating for 30 min at 70˚C. After cooling, the mixture was filtered, and the
filtrate was poured in water. The precipitate was collected, dried and purified by flash
column chromatography (Isolera 1, Biotage, 25 g size, elution gradient 12-60% ethyl
acetate in hexanes) to afford 5 as a yellow solid.
Ethyl 2-amino-5-phenylthiophene-3-carboxylate (5). 1H NMR (DMSO, 500
MHZ): δ 7.48-7.44 (m, 4H), 7.33 (t, J = 7.7 Hz, 2H), 7.23 (s, 1H), 7.19 (t, J = 7.4 Hz,
1H), 4.21 (q, J = 7.1 Hz, 2H, 1.28 (t, J = 7.1 Hz, 3H); MS (ESI): m/z 248.5 (M++H).
6-phenylthieno[2,3-d]pyrimidin-4(3H)-one (6). Compound 5 (1.15 g, 4.65 mmol)
was dissolved in excess formamide and the resulting mixture was heated for 16 h at
160˚C. The mixture was concentrated in vacuo and purified by flash column
chromatography (Isolera 1, Biotage, 25 g size, elution gradient 12-60% ethyl acetate in
hexanes) to afford 6 as a red solid.
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6-phenylthieno[2,3-d]pyrimidin-4(3H)-one (6). 1H NMR (CDCl3, 500 MHZ): δ
11.05 (s, 1H), 8.58 (s, 1H), 7.65-7.60 (m, 2H), 7.45 (s, 1H), 7.43-7.38 (m, 2H), 7.33-7.30
(m, 1H); MS (ESI): m/z 230.1 (M++H).
4-chloro-6-phenylthieno[2,3-d]pyrimidine (7). Compound 6 (1 g, 4.38 mmol)
and N,N-dimethylaniline (0.043 mL, 0.336 mmol) were dissolved in phosphoryl
trichloride (5.10 mL, 54.8 mmol) and the mixture was heated for 16 h to 95˚C. The
mixture was concentrated in vacuo and purified by flash column chromatography (Isolera
1, Biotage, 25 g size, elution gradient of 12-60% ethyl acetate in hexanes) to afford 7 as a
yellow solid.
4-chloro-6-phenylthieno[2,3-d]pyrimidine (7). 1H NMR (CDCl3, 500 MHZ): δ
8.85 (s, 1H), 7.79-7.77 (m, 2H), 7.62 (s, 1H), 7.54-7.46 (m, 3H); MS (ESI): m/z 247.1
(M++H).
General procedure for the amination of 4-chloro-6-phenylthieno[2,3d]pyrimidine. In a microwave tube, compound 7 (1 equiv), amine (1.5 equiv) and
triethylamine (3 equiv) were dissolved in ethanol and subjected to microwave heating for
1 h at 150˚C. The mixture was extracted with Ethyl Acetate/Water and the organic phase
was washed with brine, dried (Na2SO4) and concentrated in vacuo. The residue was
purified by column chromatography (Isolera 1, Biotage, elution gradient of 20-85% ethyl
acetate in hexanes) to afford the targeted compound.
3-((6-phenylthieno[2,3-d]pyrimidin-4-yl)amino)propan-1-ol (1). 1H NMR
(CDCl3, 400 MHZ): δ 8.48 (s, 1H), 7.69-7.67 (m, 1H), 7.67-7.66 (m, 1H), 7.48-7.43 (m,
2H), 7.41-7.37 (m, 1H), 7.33 (s, 1H), 5.70 (br, 1H), 3.85 (q, J = 6.5 Hz, 2H), 3.74 (t, J =
5.9 Hz, 2H), 1.93-1.87 (m, 2H); MS (ESI): m/z 286.1 (M++H).
3-(methyl(6-phenylthieno[2,3-d]pyrimidin-4-yl)amino)propan-1-ol (8). 1H NMR
(CDCl3, 400 MHZ): δ 8.41 (s, 1H), 7.74 (s, 1H), 7.70-7.64 (m, 2H), 7.49-7.43 (m, 2H),
7.41-7.36 (m, 1H), 4.67 (br, 1H), 3.96 (dd, J = 6.8, 5.4 Hz, 2H), 3.61-3.60 (m, 2H), 3.51
(s, 3H), 1.96-1.90 (m, 2H); MS (ESI): m/z 301.1 (M++H).
2-((6-phenylthieno[2,3-d]pyrimidin-4-yl)amino)ethan-1-ol (9). 1H NMR (CDCl3,
400 MHz) δ 8.45 (d, J = 2.7 Hz, 1H), 7.72-7.60 (m, 2H), 7.43 (ddt, J = 9.5, 7.8, 1.5 Hz,
2H), 7.40-7.30 (m, 2H), 5.70 (s, 1H), 3.93 (dt, J = 5.0, 3.3 Hz, 2H), 3.82 (ddt, J = 7.2,
5.4, 3.0 Hz, 2H); MS (ESI): m/z 273.1 (M++H).
2-((6-phenylthieno[2,3-d]pyrimidin-4-yl)amino)propan-1-ol (10). 1H NMR
(CDCl3, 400 MHZ): δ 8.38 (s, 1H), 7.62-7.57 (m, 2H 1.32 (d, J = 6.8 Hz, 3H), 7.37 (ddd,
J = 7.7, 6.6, 1.6 Hz, 2H), 7.31-7.25 (m, 2H), 5.24 (d, J = 6.7 Hz, 1H), 4.42-4.40 (m, 1H),
3.81 (dd, J = 10.9, 3.1 Hz, 1H),3.68-3.64 (m, 1H); MS (ESI): m/z 286.9 (M++H).
1-((6-phenylthieno[2,3-d]pyrimidin-4-yl)amino)propan-2-ol (11). 1H NMR
(DMSO, 400 MHZ): δ 8.33 (s, 1H), 8.12 (s, 1H), 7.99 (t, J = 5.9 Hz, 1H), 7.69 (d, J = 7.5
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Hz, 2H), 7.51 (t, J = 6.8 Hz, 2H), 7.42-7.38 (m, J = 7.5 Hz, 1H), 4.86 (d, J = 4.8 Hz, 1H),
3.94-3.89 (m, 1H), 3.54-3.38 (m, 2H), 1.13 (d, J = 6.2 Hz, 3H); MS (ESI): m/z 268.7
(M++H).
(S)-2-((6-phenylthieno[2,3-d]pyrimidin-4-yl)amino)propan-1-ol (12). 1H NMR
(CDCl3, 400 MHZ): δ 8.47 (s, 1H), 7.71-7.68 (m, 2H), 7.46 (t, J = 7.5 Hz, 2H), 7.41-7.39
(m, 1H), 7.35 (s, 1H), 5.31 (s, 1H), 4.51-4.49 (m, 1H), 3.91 (dd, J = 11.1, 3.02 Hz, 1H),
3.75 (dd, J = 11.1, 6.2 Hz, 1H), 1.41 (d, J = 6.9 Hz, 3H); MS (ESI): m/z 286.9 (M++H).
(R)-2-((6-phenylthieno[2,3-d]pyrimidin-4-yl)amino)propan-1-ol (13). 1H NMR
(CDCl3, 400 MHZ): δ 8.47 (s, 1H), 7.70-7.68 (m, 2H), 7.46 (t, J = 8.2 Hz, 2H), 7.41-7.35
(m, 2H), 5.33 (s, 1H), 4.52-4.48 (m, 1H), 3.93-3.88 (m, 1H), 3.78-3.73 (m, 1H), 1.41 (d, J
= 6.4 Hz, 3H); MS (ESI): m/z 286.9 (M++H).
N-(1-methoxypropan-2-yl)-6-phenylthieno[2,3-d]pyrimidin-4-amine (14). 1H
NMR (DMSO, 400 MHZ): δ 8.34 (s, 1H), 8.12 (s, 1H), 7.74-7.68 (m, 3H), 7.51 (t, 2H, J
= 7.4 Hz), 7.43-7.38 (m, 1H), 4.60-4.53 (m, 1H), 3.52-3.48 (m, 1H), 3.40-3.37 (m, 1H),
3.30 (s, 3H), 1.24 (d, J = 6.7 Hz, 3H); MS (ESI): m/z 300.8 (M++H).
4-((6-phenylthieno[2,3-d]pyrimidin-4-yl)amino)butan-1-ol (15). 1H NMR
(CDCl3, 400 MHZ): δ 8.47 (s, 1H), 7.67-7.64 (m, 2H), 7.45-7.25 (m, 4H), 5.67 (s, 1H),
3.79 (s, 2H), 3.69 (s, 2H), 2.16 (s, 1H), 1.87-1.84 (m, 2H), 1.75-1.73 (m, 2H); MS (ESI):
m/z 301.3 (M++H).
2-((6-phenylthieno[2,3-d]pyrimidin-4-yl)amino)butan-1-ol (16). 1H NMR
(CDCl3, 400 MHZ): δ 8.45 (s, 1H), 7.70-7.67 (m, 2H), 7.48-7.43 (m, 2H), 7.39 (t, J =
7.48 Hz, 1H), 7.35 (s, 1H), 5.34 (d, J = 7.5 Hz, 1H), 4.33-4.26 (m, 1H), 3.93 (dd, J =
11.1, 3 Hz, 1H), 3.80 (dd, J = 11.1, 5.8 Hz, 1H), 1.88-1.70 (m, 2H), 1.09 (t, J = 7.2 Hz,
3H); MS (ESI): m/z 300.9 (M++H).
1-((6-phenylthieno[2,3-d]pyrimidin-4-yl)amino)butan-2-ol (17). 1H NMR
(DMSO, 400 MHZ): δ 8.33 (s, 1H), 8.12 (s, 1H), 7.96 (t, J = 5.73 Hz, 1H), 7.70-7.67 (m,
2H), 7.51 (dd, J = 8.41, 7.01 Hz, 2H), 7.42-7.38 (m, 1H), 4.83 (d, J = 5.24 Hz, 1H), 3.703.62 (m, 1H), 3.61-3.55 (m, 1H), 3.44-3.37 (m, 1H), 1.58-1.48 (m, 1H), 1.42-1.31 (m,
1H), 0.93 (t, J = 7.4 Hz, 3H); MS (ESI): m/z 300.9 (M++H).
3-methyl-2-((6-phenylthieno[2,3-d]pyrimidin-4-yl)amino)butan-1-ol (18). 1H
NMR (CDCl3, 400 MHZ): δ 8.35 (s, 1H), 7.62-7.59 (m, 2H), 7.37 (t, J = 7.2 Hz, 2H),
7.32-7.25 (m, 2H), 5.30 (d, J = 7.7 Hz, 1H), 4.11-4.05 (m, 1H), 3.87-3.75 (m, 2H), 3.48
(m, 1H), 2.10-2.01 (m, 1H), 1.20-0.98 (m, 6H); MS (ESI): m/z 315.01 (M++H).
N-(3,4-dimethoxyphenethyl)-6-phenylthieno[2,3-d]pyrimidin-4-amine (19). 1H
NMR (CDCl3, 400 MHZ): δ 8.54 (s, 1H), 7.65 (d, J = 7 Hz, 2H), 7.45 (t, J = 7.04 Hz,
2H), 7.40-7.36 (m, 1H), 7.20 (s, 1H), 6.88-6.78 (m, 3H), 5.28 (br, 1H), 3.95-3.90 (m,
5H), 3.87 (s, 3H), 2.99 (t, J = 7.04 Hz, 2H); MS (ESI): m/z 392.01 (M++H).
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N-(3,4-dimethylphenethyl)-6-phenylthieno[2,3-d]pyrimidin-4-amine (20). 1H
NMR (DMSO, 400 MHZ): δ 8.37 (s, 1H), 8.07 (t, J = 5.62 Hz, 1H), 8.00 (s, 1H), 7.67 (d,
J = 7.52 Hz, 2H), 7.51 (t, J = 8.08 Hz, 2H), 7.40 (t, J = 7.12 Hz, 1H), 7.06-7.05 (m, 2H),
6.99-6.97 (m, 1H), 3.73-3.68 (m, 2H), 2.87 (t, J = 7.49 Hz, 2H), 2.19 (s, 3H), 2.17 (s,
3H); MS (ESI): m/z 361.21 (M++H).
6-phenyl-N-(2-(pyridin-4-yl)ethyl)thieno[2,3-d]pyrimidin-4-amine (21). 1H
NMR (CDCl3, 400 MHZ): δ 8.56-8.47 (m, 3H), 7.65-7.63 (m, 2H), 7.44-7.41 (m, 2H),
7.38-7.36 (m, 1H), 7.21-7.18 (m, 3H), 5.26 (s, 1H), 3.98-3.93 (m, 2H), 3.05 (t, 2H, J =
7.52 Hz); MS (ESI): m/z 333.1 (M++H).
6-phenyl-N-(2-(pyridin-3-yl)ethyl)thieno[2,3-d]pyrimidin-4-amine (22). 1H
NMR (CDCl3, 400 MHZ): δ 8.56-8.53 (m, 3H), 7.68-7.65 (m, J = 6.88 Hz, 2H), 7.61 (d,
J = 7.91 Hz, 1H), 7.45 (dd, J = 8.45, 6.60 Hz, 2H), 7.40-7.37 (m, 1H), 7.24 (s, 1H), 5.26
(s, 1H) 3.96 (q, J = 6.73, 2H), 3.08 (t, J = 6.96 Hz, 2H); MS (ESI): m/z 333.1 (M++H).
N-(2,3-dimethoxybenzyl)-6-phenylthieno[2,3-d]pyrimidin-4-amine (23). 1H
NMR (CDCl3, 400 MHz) δ 8.54 (s, 1H), 7.69-7.63 (m, 2H), 7.49-7.41 (m, 2H), 7.40-7.33
(m, 1H), 7.30 (d, J = 1.2 Hz, 1H), 7.11-7.00 (m, 2H), 6.94 (dd, J = 7.8, 1.8 Hz, 1H), 5.73
(s, 1H), 4.89 (d, J = 5.6 Hz, 2H), 3.97 (d, J = 0.9 Hz, 3H), 3.92 (d, J = 1.1 Hz, 3H); MS
(ESI): m/z 379.02 (M++H).
3-(4-methoxyphenyl)-2-((6-phenylthieno[2,3-d]pyrimidin-4-yl)amino)propan-1ol (24). 1H NMR (CDCl3, 500 MHZ): δ 8.38 (s, 1H), 7.55 (d, J = 7.65 Hz, 2H), 7.36 (t, J
= 7.54 Hz, 2H), 7.30 (t, J = 7.7 Hz, 1H), 7.14-7.11 (m, 3H), 6.80 (d, J = 8.2 Hz, 2H), 5.39
(d, J = 6.25 Hz, 1H), 4.45-4.39 (m, 1H), 3.82 (d, J = 10.8 Hz, 1H), 3.72-3.66 (m, 4H),
2.97-2.80 (m, 2H); MS (ESI): m/z 391.9 (M++H).
2-(4-methoxyphenyl)-2-((6-phenylthieno[2,3-d]pyrimidin-4-yl)amino)ethan-1-ol
(25). 1H NMR (CDCl3, 400 MHZ): δ 8.38 (s, 1H), 7.59 (dd, J = 8.19, 1.45 Hz, 2H), 7.36
(td, J = 7.63, 6.91, 1.15 Hz, 2H), 7.32-7.27 (m, 4H), 6.86 (d, J = 8.48 Hz, 2H), 5.65 (d, J
= 6.22 Hz, 1H), 5.35-5.31 (m, 1H), 4.01-3.98 (m, 2H), 3.75 (s, 3H), 3.57 (s, 1H); MS
(ESI): m/z 378.1 (M++H).
(R)-2-(4-methoxyphenyl)-2-((6-phenylthieno[2,3-d]pyrimidin-4-yl)amino)ethan1-ol (26). 1H NMR (DMSO, 400 MHZ): δ 8.28 (s, 1H), 8.24 (s, 1H), 8.13 (d, J = 8.2 Hz,
1H), 7.73-7.70 (m, 2H), 7.54-7.50 (m, J = 8.12 Hz, 2H), 7.43-7.39 (m, 1H), 7.37-7.34 (m,
2H), 6.89 (d, J = 8.6 Hz, 2H), 5.43-5.38 (m, 1H), 4.99 (t, J = 6.16 Hz, 1H), 3.79-3.69 (m,
5H); MS (ESI): m/z 378.1 (M++H).
(S)-2-(4-methoxyphenyl)-2-((6-phenylthieno[2,3-d]pyrimidin-4-yl)amino)ethan1-ol (27). 1H NMR (DMSO, 400 MHZ): δ 8.28 (s, 1H), 8.24 (s, 1H), 8.14 (d, J = 7.76 Hz,
1H), 7.72 (d, J = 8.2 Hz, 2H), 7.52 (t, J = 7.72 Hz, 2H), 7.43-7.35 (m, 3H), 6.89 (d, J = 9
Hz, 2H), 5.41 (q, J = 7.88 Hz, 1H), 4.99 (t, J = 6.04 Hz, 1H), 3.79-3.69 (m, 5H); MS
(ESI): m/z 378.1 (M++H).
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(R)-2-phenyl-2-((6-phenylthieno[2,3-d]pyrimidin-4-yl)amino)ethan-1-ol (28). 1H
NMR (CDCl3, 400 MHZ): δ 8.46 (s, 1H), 7.69 (d, J = 6.88 Hz, 2H), 7.47-7.34 (m, 9H),
5.85 (s, 1H), 5.50-5.47 (m, 1H), 4.17-4.09 (m, 2H); MS (ESI): m/z 348.9 (M++H).
(R)-2-(2-fluoro-4-methoxyphenyl)-2-((6-phenylthieno[2,3-d]pyrimidin-4yl)amino)ethan-1-ol (29). 1H NMR (CDCl3, 400 MHZ): δ 8.45 (s, 1H), 7.67 (d, J = 6.16
Hz, 2H), 7.45-7.29 (m, 5H), 6.70 (s, 2H), 6.02 (s, 1H), 5.70 (s, 1H), 4.14-4.05 (m, 2H),
3.81 (s, 3H); MS (ESI): m/z 396.01 (M++H).
(R)-2-(2-fluoro-4-methoxyphenyl)-2-((6-phenylthieno[2,3-d]pyrimidin-4yl)amino)ethan-1-ol (30). 1H NMR (CDCl3, 400 MHZ): δ 8.42 (s, 1H), 7.67-7.65 (m,
2H), 7.54 (s, 1H), 7.45-7.35 (m, 3H), 7.22-7.16 (m, 2H), 6.98 (t, J = 8.6 Hz, 1H), 6.31 (s,
1H), 5.45-5.41 (m, 1H), 4.14-4.06 (m, 2H), 3.90 (s, 3H); MS (ESI): m/z 397.3 (M++H).
Compounds 37-40 were synthesized following the General procedure for the
amination of 4-chloro-6-phenylthieno[2,3-d]pyrimidine.
(R)-2-((5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol
(37). 1H NMR (CDCl3, 400 MHZ): δ 8.35(s, 1H), 7.44-7.28 (m, 5H), 6.28 (s, 1H), 5.475.43 (m, 1H), 4.07 (d, J = 4.58 Hz, 2H), 2.51 (s, 3H), 2.46 (s, 3H); MS (ESI): m/z 301.00
(M++H).
(R)-2-((5-methyl-6-phenylthieno[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1ol (38). 1H NMR (CDCl3, 400 MHZ): δ 8.48 (s, 1H), 7.48-7.36 (m, 9H), 7.11-7.07 (m,
1H), 5.89 (d, J = 6.84 Hz, 1H), 5.49 (q, J = 5.44 Hz, 1H), 4.17-4.09 (m, 2H), 1.28 (s, 3H);
MS (ESI): m/z 361.9 (M++H).
(R)-2-((6-methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1ol (39). 1H NMR (CDCl3, 400 MHZ): δ 8.42 (s, 1H), 7.57 (t, J = 7.63 Hz, 1H), 7.45-7.41
(m, 2H), 7.27-7.21 (m, 5H), 6.90-6.88 (m, 2H), 5.33 (d, J = 5.6 Hz, 1H), 5.20-5.16 (m,
1H), 3.78-3.69 (m, 2H), 2.33 (s, 3H); MS (ESI): m/z 361.9 (M++H).
(R)-2-phenyl-2-((5-phenylthieno[2,3-d]pyrimidin-4-yl)amino)ethan-1-ol (40). 1H
NMR (CDCl3, 400 MHZ): δ 8.45 (s, 1H), 7.69-7.67 (m, 2H), 7.47-7.35 (m, 9H), 5.965.94 (m, 1H), 5.51-5.47 (m, 1H), 4.17-4.10 (m, 2H); MS (ESI): m/z 348.1 (M++H).
Synthesis of Amine Analog 31
tert-butyl (R)-(1-(3-fluoro-4-methoxyphenyl)-2-hydroxyethyl)carbamate (33).
Di-tert-butyl dicarbonate (0.290 g, 1.329 mmol) was added to a solution of (R)-1-(3fluoro-4-methoxyphenyl)-2-hydroxyethanaminium chloride 32 (0.267 g, 1.208 mmol)
and triethylamine (0.506 mL, 3.63 mmol) in DCM (4 mL). The reaction mixture was
stirred for 2 h at room temperature. The mixture was concentrated and purified by flash
column chromatography (Isolera 1, Biotage, 10 g size, elution gradient 12-80% ethyl
acetate in hexanes). Pure fractions were evaporated to afford 33 as a white solid.
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tert-butyl (R)-(1-(3-fluoro-4-methoxyphenyl)-2-hydroxyethyl)carbamate (33). 1H
NMR (CDCl3, 500 MHZ): δ 7.08-7.03 (m, 2H), 6.96 (t, J = 8.33 Hz, 1H), 5.21 (d, J =
6.55 Hz, 1H), 4.73 (s, 1H), 3.90-3.81 (m, 5H), 2.11 (s, 1H), 1.46 (s, 9H); MS (ESI): m/z
284.3 (M++H).
tert-butyl (R)-(2-(1,3-dioxoisoindolin-2-yl)-1-(3-fluoro-4methoxyphenyl)ethyl)carbamate (34).144 DIAD (0.282 mL, 1.458 mmol) was added
dropwise at room temperature, to a solution of 33 ( 0.320 g, 1.122 mmol), phthalimide
(0.215 g, 1.458 mmol) and Ph3P (0.382 g, 1.458 mmol) in THF (3.8 mL). The resulting
mixture was stirred for 16 h at room temperature. The mixture was extracted with Ethyl
Acetate/Water and the organic phase was washed with brine, dried (Na2SO4) and
evaporated in vacuo. The residue was purified by flash column chromatography (Isolera
1, Biotage, 10 g size, elution gradient 12-60% ethyl acetate in hexanes), to afford 34 as a
yellow solid.
tert-butyl (R)-(2-(1,3-dioxoisoindolin-2-yl)-1-(3-fluoro-4methoxyphenyl)ethyl)carbamate (34). 1H NMR (CDCl3, 500 MHZ): δ 7.80 (m, 2H), 7.66
(m, 2H), 7.04 (m, 2H), 6.87 (m, 1H), 5.28 (d, J = 8.1 Hz, 1H), 4.94-4.92 (m, 1H), 3.893.81 (m, 5H), 1.20 (s, 9H); MS (ESI): m/z 415.7 (M++H).
(R)-2-(2-amino-2-(3-fluoro-4-methoxyphenyl)ethyl)isoindoline-1,3-dione (35)
and (R)-2-(2-(3-fluoro-4-methoxyphenyl)-2-((6-phenylthieno[2,3-d]pyrimidin-4yl)amino)ethyl)isoindoline-1,3-dione (36). HCl (4 M in 1,4-dioxane, 0.9 mL, 3.6 mmol)
was added to a solution of 34 (0.372 g, 0.897 mmol) in a mixture of DCM (2.5 mL) and
methanol (1 mL), and the resulting mixture was stirred for 16 h at room temperature. The
mixture was subjected to acid-base extraction with Ethyl Acetate/Water and the organic
phase was washed with brine, dried (Na2SO4) and concentrated in vacuo. The resulting
residue 35 (yellow oil) was used in the next step without further purification. 36 was
synthesized following the general procedure for amination of 4-chloro-6phenylthieno[2,3-d]pyrimidine.
(R)-2-(2-amino-2-(3-fluoro-4-methoxyphenyl)ethyl)isoindoline-1,3-dione (35).
H NMR (MeOD, 500 MHZ): δ 7.88-7.78 (m, 4H), 7.20 (dd, J = 12.4, 2.20 Hz, 1H), 7.08
(dd, J = 8.65, 2.14 Hz, 1H), 7.00(t, J = 8.49 Hz, 1H), 4.25 (t, J = 7.27 Hz, 1H), 3.88-3.84
(m, 5H); MS (ESI): m/z 315.5 (M++H).
1

(R)-2-(2-(3-fluoro-4-methoxyphenyl)-2-((6-phenylthieno[2,3-d]pyrimidin-4yl)amino)ethyl)isoindoline-1,3-dione (36). 1H NMR (CDCl3, 500 MHZ): δ 8.31 (s, 1H),
7.88-7.85 (m, 2H), 7.75-7.73 (m, 4H), 7.54 (s, 1H), 7.49 (t, J = 7.55, 1H), 7.42 (t, J =
7.35 Hz, 1H), 7.25-7.22 (m, 2H), 6.99-6.95 (m, 1H), 6.91 (s, 1H), 5.66-5.62 (m, 1H),
4.24-4.12 (m, 2H), 3.89 (s, 3H); MS (ESI): m/z 525.5 (M++H).
(R)-1-(3-fluoro-4-methoxyphenyl)-N1-(6-phenylthieno[2,3-d]pyrimidin-4yl)ethane-1,2-diamine (31). Compound 36 ( 0.203 g, 0.393 mmol) was dissolved in
methanol and a 80 % hydrazine hydrate solution (0.073 mL,1.2 mmol) was added
dropwise to the solution at 0˚C. The reaction mixture was stirred for 16 h at room
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temperature. The mixture was extracted with Ethyl Acetate/Water and the organic phase
was washed with brine, dried (Na2SO4) and evaporated in vacuo. The residue was
purified by flash column chromatography (Isolera 1, Biotage, 10 g size, elution gradient
2-20 % methanol in ethyl acetate) to afford 31 as a yellow solid.
(R)-1-(3-fluoro-4-methoxyphenyl)-N1-(6-phenylthieno[2,3-d]pyrimidin-4yl)ethane-1,2-diamine (31). 1H NMR (DMSO, 500 MHZ): δ 8.27 (s, 1H), 8.15 (s, 1H),
7.75 (d, 2H, J = 7.6 Hz), 7.54 (t, 2H, J = 7.6 Hz), 7.44 (t, 1H, J = 7.6 Hz), 7.26 (dd, J =
12.5, 2 Hz, 1H), 7.20 (d, 1H, J = 7.6 Hz), 7.12 (t, J = 8.6 Hz, 1H), 5.28-5.25 (m, 1H),
3.80 (s, 3H), 3.00-2.91 (m, 2H), 1.25-1.18 (m, 2H); MS (ESI): m/z 396.4 (M++H).
H. pylori IC50 Dose Responses
H. pylori strains ATCC 43504, SS1, or SS1 NuoD A402P (see below) were
grown overnight in brucella broth containing Skirrow’s selective medium supplement 1
and 10% FBS or brain heart infusion broth containing Skirrow’s and 10% FBS. Cultures
were grown in vented 25-cm2 tissue culture flasks at 37°C, 10% CO2 with rotation at 50
rpm. Two-fold serial dilutions of test and control compounds were performed in DMSO
or water as appropriate and 1 uL was transferred to a 96 well plate. 99 uL of a 1:10
dilution of an overnight culture of H. pylori in Brucella/Skirrow’s/10% FBS was added to
each well. Plates were incubated for 18-20 h, and 5 ul of 3mM resazurin was added to
each well. Plates were incubated for an additional 3-5 h, and resazurin reduction was
measured using a BioTek Synergy Mx (BioTek, Winooski, VT) with an excitation
wavelength of 540nm and emission read at 590nm. Percent inhibition compared to
growth controls were calculated and the 50% inhibitory concentration (IC50) was
determined using XLFit software (IDBS, London, United Kingdom).
Cytotoxicity Assays
FaDu (ATCC HTB-43) and HepG2 (ATCC HB-8065) cell lines were routinely
maintained according to the protocols provided by the American Type Culture Collection
(ATCC). For cytotoxicity IC-50 determination, 100uL of cell suspension in Eagle’s
Minimal Essential Medium supplemented with 10% FBS was seeded into black sided,
tissue culture treated 96 well plates (Corning 3603) at a concentration of 3 x 105 cells/ml.
Plates were incubated for 24 hours in a 37°C, 5% CO2 incubator to allow for cell
adhesion and growth. Spent media was aspirated from the test plates and serial two-fold
dilutions of test compounds mixed with fresh EMEM + 10% FBS were added to the
plates at 100 μL per well. The final DMSO concentration was 1%. The plates were
incubated for 72 hours. The media was aspirated and FBS-free EMEM and resazurin
(final concentration 0.15 mM) was added to the plate. Plates were incubated for 3-5 hours
and then resazurin reduction was measured using a BioTek Synergy Mx (BioTek,
Winooski, VT) with an excitation wavelength of 540nm and emission read at 590nm.
Percent inhibition compared to growth controls were calculated and the 50% inhibitory
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concentration (IC50) curves were generated using XLFit software (IDBS, London,
United Kingdom).
Generation of Resistant Mutants, Sequencing and Target Identification
Mutants resistant to the thienopyrimidine series were generated in two separate
ways. Strain HM-274 was chosen for these studies, since it had been previously
annotated. Spontaneous mutants of HM-274 were selected by concentrating and
harvesting susceptible wildtype cultures and spreading them onto plates containing 2X
MIC of 28 . Two stably resistant isolates were recovered which had MICs 8-fold higher
than the wildtype. H. pylori ATCC 43504 was serially passaged onto plates containing
increasingly higher concentrations of 1 until the strain was able to grow at 8X the MIC
of the wild-type. The DNA from this resistant mutant was then purified and transformed
into strain HM-274 and resistance was confirmed. Genomic DNA was purified from the
three resistant mutants as well as HM-274 wildtype using ZR Fungal/Bacterial DNA
MiniPrep (Zymo Research) according to the manufacturer’s instructions. Whole genome
sequencing was performed by Tufts Medical Center. Genome annotation was
accomplished using RAST and single nucleotide polymorphism (SNP) identification was
performed with CLC Workbench. The two spontaneous resistant mutants had SNPs in
nuoD which caused one amino acid change, either A402P or T400I. The serial passage
mutant had multiple non-synonymous mutations in nuoD. There were no other shared
mutations in all three strains.
Seven additional spontaneous resistant mutants were isolated. Genomic DNA was
purified from each and nuoD was amplified by PCR. The PCR products were sequenced
and compared to wildtype nuoD. All seven had mutations in nuoD resulting in an amino
acid change, either A402P or T400I.
In order to ensure that no secondary mutations were causing thienopyrimidine
resistance, a wild-type copy of nuoD was modified to contain the A402P mutation using
the Q5 Site Directed Mutagenesis kit (New England Biolabs) according to the
manufacturer’s instructions. The mutation was confirmed by PCR and then wild-type SS1
was transformed with this plasmid and selected for on plates containing 28. The A402P
mutation in nuoD conferred resistance in strain SS1. Several colonies were chosen and
the mutation was confirmed by PCR and sequencing. An SS1 isolate with the NuoD
A402P mutation was used in further testing to confirm on target activity of the
thienopyrimidine series (see above).
ex vivo Efficacy Study
This model was modified from what has previously been described 2-4. Briefly, 6to 8-week-old female C57BL/6 (specific-pathogen-free) mice were obtained from
Charles River Laboratories. Five mice were housed per cage and allowed to acclimate for
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at least 72 h. Animals were inoculated by oral gavage, three times within one week with
0.2 ml of an H. pylori SS1 suspension (~109 CFU/dose). The infection was allowed to
stabilize for one to two weeks after the final gavage. Mice were euthanized and the
stomachs were excised, bisected laterally into equal halves along the long curvature, and
washed three times with sterile PBS. Each half was then added to the well of a 12 well
plate containing Brucella broth supplemented with 10% FBS and Skirrow’s with or
without 100X the MIC of Compound 25. Each half from individual stomachs were
assigned to a control and treatment group. After 24 h, the stomach halves were washed,
weighed, homogenized, serially diluted, and plated on selective medium. These plates
were incubated for 7 days and then colonies were counted to determine colony counts.
Data was log transformed and statistical significance was determined using a MannWhitney test with GraphPad Prism software. A P-value less than 0.05 was considered
significant. The study was repeated to ensure reproducibility. Animal use complied with
the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the
Office of Laboratory Animal Welfare.
Homology Modeling of H. pylori’s Complex I
A homology model of the subunits NuoD and NuoB of NADH:ubiquinone
Oxidoreductase in Helicobacter pylori was created using Schrodinger’s Maestro
program. The homology model was built using the protein sequence from a Thermus
thermophilus crystal structure (PDB 2FUG) as a template to build the NuoD and NuoB
subunits of NADH:quinone oxidoreductase in H. pylori. A series of thienopyrimines and
two known complex I inhibitors were docked using Schrodinger’s Induced Fit docking
based upon the quinone binding channel, based on previous Thermus thermophilus and
mitochondrial studies of ubiquinone binding (Tyr85, Arg40, Val403, and Asn401), and
from a ligand in our thienopyrimidine series (T400 and A402).7 All residue numbers are
based on the protein sequence of H. pylori. A multiple sequence alignment was
performed with mouse, bovine, human, A. fumagatis, H. pylori, E. coli and M.
tuburculosis using CLC Genomic Workbench 11.
Results and Discussion
New compounds were synthesized to develop the SAR around the two
thienopyrimidine hits as outlined in Scheme 2-1.125-128 First, phenylacetaldehyde 3 is
reacted with ethyl 3-cyanopropanoate 4 to give phenylthiophene 5. Heating 5 in the
excess of formamide formed pyrimidone 6. Chlorination and dehydration of the
pyrimidone with phosphoryl chloride afforded the chlorothienopyrimidine 7, which was
coupled with a variety of primary and a secondary amine to give targeted 4-position
substituted H. pylori inhibitors (8-30). These amines were selected based on their
structural resemblance to the amine substituents of the hit compounds and the progress of
the anti-H. pylori SAR. Initial SAR efforts focused on exploring the 4-position of the
thienopyrimidine core, examining the N-alkyl hydroxyl moiety of hit compound 1, Series
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Scheme 2-1. Synthesis of thienopyrimidine derivatives.

Reagents and conditions: (i) Sulfur, Morpholine, Ethanol, 70˚C, Microwave, 20 min,
90%; (ii) Formamide, reflux, 18 h, 80%; (iii) POCl3, N, N dimethylaniline, reflux, 14 h,
90%; (iv) Ethanol, 150˚C, Microwave, 1 h, 80-93%.
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1 (Table 2-1) and phenethyl amine motif of compound 2, Series 2 (Table 2-2). These
sidechains were then successful merged into Series 3 (Table 2-3). Commercially
available amine starting materials with hydroxyl and aromatic moieties, similar to the
moieties identified with the hit compounds, were used to synthesize analogs in these
series to investigate the SAR at the 4-position.
In series 1, thienopyrimidines variation to the propyl alcohol like substituent of hit
compound 1 were examined (Table 2-1). Compound 8 was generated first to investigate
the effect of N-methylation of the amine group attached at the 4-position of the
thienopyrimidine found in hit compound 1. Compound 8 demonstrates less anti-H. pylori
activity and also increases the lipophilicity negatively impacting the Lipophilic
Efficiency (LLE), suggesting that the free secondary amine is preferred in this series. To
optimize the spacer between the hydroxyl group and the amine moiety, we synthesized
compound 9 with an ethyl motif as spacer. Compared to hit compound 1, 9 demonstrates
less activity compared to compound 1, suggesting that a propyl linker is preferred for
improved potency. To investigate branching between the amine moiety at the 4-position
and the hydroxyl group of compound 1, we synthesized methyl branched isomers 10 and
11. Compound 10 demonstrates higher potency and selectivity compared to compound
11, suggesting further SAR development are preferred at the α-carbon to the amine over
the β carbon. The methylation creates a chiral center, the contribution of each isomer in
10 was examined through the synthesis of enantiomers 12 (S) and 13 (R). The R
enantiomer 13 demonstrates 75-fold increased activity over the S enantiomer 12. To
examine the contribution of the hydroxyl group, we synthesized compound 14, the Omethylated analog of 10. Compared to compound 10, 14 demonstrates less potency with
a large decrease in LLE, suggesting that the free hydroxyl group is desired for optimal
activity. To expand on the linker region, we synthesized isomeric compounds 15, 16 and
17 with an additional methylene unit. Compound 16, α-carbon ethyl substituted analog,
demonstrates the highest potency of these 3 isomers consistent with previously developed
SAR. Compound 18, with a bulkier isopropyl substitution over the ethyl motif found in
16, showed much decreased potency. Overall, within this compound series clear SAR
was observed consistent with the analogs engaging a defined molecular target.
Next compounds we examined how phenethyl sidechain of compound 2 performs
on the 6-phenyl- thienopyrimidine core found in the first series, four analogs with varying
phenyl substitutions were designed and synthesized 19, 20, 21 and 22 (Table 2-2). Best
among these compounds, 19 displays the excellent potency and selectivity against H.
pylori. 19 is the direct phenyl- thienopyrimidine hybrid of 2 with the 3,4dimethoxyphenethyl side chain. Substitution of the dimethoxyphenyl motif with
dimethylphenyl, compound 20, decrease comparative potency and increased lipophilicity.
3 and 4 substituted pyridyl analogs (21 and 22) designed to increase metabolic stability
and solubility also showed substantially decreased potency, suggesting the
dimethoxyphenylethyl substitution provides optimum anti-H. pylori activity. To
determine the optimum spacer for the phenyl moiety, we synthesized compound 23 with
a methylene motif as spacer. 23 demonstrates less potency compared to 19, suggesting
the ethyl motif is preferred as spacer for this series of compounds.
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Table 2-1.

The structure-activity relationship of thienopyrimidines of series 1.

Compound

Log P

H. pylori
IC50 ± SEM
(μg/mL)
SS1 straina

1

3.36

0.46
± 0.07

75.4
± 42.6

-1.92

8

4.14

1.85
± 1.48

29.55
± 2.82

-1.16

9

3.25

0.546
± 0.219

28.21
± 5.36

-1.77

10

3.57

0.05
± 0.09

26.74
± 4.57

-2.68

11

3.57

0.13
± 0.07

18.54
± 0.97

-1.74

12

3.57

0.98
± 0.71

79.44
± 14.31

-1.57

13

3.57

0.01
± 0.01

8.17
± 1.10

-2.69

14

3.93

0.16
± 0.09

10.13
± 1.93

-2.38

15

3.81

0.18
± 0.12

55.27
± 1.59

-2.71

16

4.05

0.02
± 0.00

11.66
± 0.05

-3.24

17

4.05

0.09
± 0.05

12.25
± 0.05

-2.65

18

4.45

0.24
± 0.05

15.64
± 5.08

-3.37

a All

IC50 data are the mean of 3 measurements.
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b LLE

Cytotoxicity
IC50 ± SEM
(μg/mL)
FaDu Cellsa

LLE b

= pIC50 – log P.

Table 2-2.

The structure-activity relationship of thienopyrimidines of series 2.

Compound

Log P

H. pylori
IC50 ± SEM
(μg/mL)
SS1 straina

19

5.53

0.02
± 0.002

133.34
± 57.73

-4.69

20

6.75

0.22
± 0.17

<6.25
± 0.00

--5.83

21

4.44

0.48
± 0.32

29.32
± 4.81

-3.32

22

4.44

1.08
± 0.47

30.31
± 0.64

-2.72

23

5.25

0.237
± 0.167

9.72
± 3.00

-3.91

a All

IC50 data are the mean of 3 measurements.
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b LLE

Cytotoxicity
IC50 ± SEM
(μg/mL)
FaDu Cellsa

LLE b

= pIC50 – log P.

Table 2-3.

The structure-activity relationship of thienopyrimidines of series 3.

Compound

Log P

H. pylori
IC50 ± SEM
(μg/mL)
SS1 straina

24

5.12

0.09
± 0.03

6.51
± 0.14

-4.07

25

4.84

0.006
± 0.003

161.58
± 33.42

-3.93

26

4.84

0.004
± 0.000

6.4
± 0.01

-3.94

27

4.84

0.05
± 0.04

21.44
± 4.19

-3.86

28

4.96

0.01
± 0.007

<6.25
± 0.00

-4.07

29

4.99

0.004
± 0.001

13.21
± 0.60

-4.08

30

4.99

0.004
± 0.000

12.42
± 0.82

-4.08

31

4.61

0.54
± 0.36

19.06
± 7.40

-2.69

a All

IC50 data are the mean of 3 measurements.

28

b LLE

Cytotoxicity
IC50 ± SEM
(μg/mL)
FaDu Cellsa

LLE b

= pIC50 – log P.

The SAR progression revealed series leads 16 and 19 from hits 1 and 2
respectively. We hypothesized that merging both substituents at the 4-position of phenylthienopyrimidine could produce analogs with increased potency. Thus, we synthesized
compound 24 (Table 2-3) which demonstrated higher activity than 16 and similar potent
activity to 19. In attempt to optimize the activity of 24 we were able to purchase several
2-phenylglycinol building block with a shorter spacer between the aryl motif and the
nitrogen. First compound 25 was generated which demonstrates the highest potency of
the series, in low ng/mL-range of activity (H.p. IC50 = 0.006 μg/ml). Both enantiomers of
25 were then synthesized. Compound 26, the R enantiomer of 25, showed higher potency
(H.p. IC50 = 0.004 μg/ml) than the S enantiomer (27). To further understand the SAR
around the phenylglycinol aryl ring, we synthesized fluorinated compounds, 28 and 29.
These compounds demonstrated comparable potency to 26.
While various aryl rings at the 4-position of compound 28-30 demonstrate
activity, we synthesized primary amine analog 31 to further elucidate the importance of
the hydroxyl moiety and the SAR at the 4-position, as primary amines have been shown
to enhance uptake of drugs into Gram-negative bacteria.129 Compound 31 was
synthesized as described in Scheme 2-2.143,144 Amine compound 32 was protected with
di-tert-butyl dicarbonate to yield the the boc-protected amine 33. Substitution of the
hydroxyl group of 33 with a phthalamide group was carried out under mitsunobu
conditions to give the intermediate 34. Next, the removal of the boc group yielded the
amine 35, which was coupled to chlorothienopyrimidine 7 to afford the intermediate 36.
In the final step, the deprotection of the phthalamide group of 36 afforded the targeted
thienopyrimidine 31. However, 31 did not show improved activity compared to 30,
suggesting the hydroxyl moiety is required for the anti-H. pylori activity.
Initial hits 1 and 2 also differ in their substitution patterns at -C5 and C6 of the
thienopyrimidine ring. Compounds 37-40 were synthesized as described in Scheme 2-3.
Commercially available chlorothienopyrimidines (41-44) were used in the coupling
reaction with the optimized phenylglycinol sidechain to yield final compounds (37-40).
The effect of substitution at these positions was then studied in combination with the
optimized phenylglycinol 4-postion sidechain. Compounds 37, 38, 39 and 40 (Table 2-4)
were generated and their activities were compared to compound 28 (Table 2-3). Moving
the phenyl ring to the 5-position (39 and 40) substantially reduced anti-H. pylori potency.
The dimethyl analog 30 with a similar substitution pattern of compound 2, showed a
slight improvement over 2 but weaker activity than the 6-phenyl substituted analog 38. 38
with a similar phenyl substitution pattern to series 3 compounds and an addition methyl
substitution, demonstrates comparable activity to 28, suggesting the phenyl ring at the 6position optimal and 5-position can be hydrogen and methyl but not a larger phenyl
group.
To determine the target of the thienopyrimidines, resistant H. pylori mutants were
successfully isolated by serial passage on agar medium containing compound 25. Upon
whole genome sequencing, two spontaneous mutants were identified containing nonsynonymous point mutations in nuoD. The resulting amino acid substitutions were T400I
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Scheme 2-2. Synthesis of amine 31.

Reagents and conditions: (i) di-tert-butyl dicarbonate, Et3N, DCM, RT, 2 h; (ii)
phthalimide, DIAD, Ph3P, DCM, RT, 4 h; (iii) 4 M HCl in dioxane, DCM, methanol, RT,
4 h; (iv) Et3N, reflux, 6 h; (v) NH2NH2, methanol, RT, 6 h.

30

Scheme 2-3. Synthesis of thienopyrimidine analogs with modifications at the 5 and
6-position.

Reagents and conditions: (i) Et3N, 150˚C, Microwave, 1 h, 89-93%.
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Table 2-4.
The structure-activity relationship of series 4 with substitutions at the
5 and 6-positions of the thienopyrimdine core.

Compound

a All

R1

R2

Log P

37

4.05

38

5.45

39

5.24

40

4.91

IC50 data are the mean of 3 measurements.
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H. pylori
IC50 ± SEM
(μg/mL)
SS1 straina
0.25
± 0.18
0.01
± 0.001
10.24
± 13.59
0.21
± 0.16
b LLE

Cytotoxicity
IC50 ± SEM
(μg/mL)
FaDu Cellsa

LLE b

24.61

-1.84

447.64

-4.51

4.37

-1.7

60.69

-2.81

= pIC50 – log P.

and A402P (Figure 2-2). The gene, nuoD encodes for the D subunit of NADH:Quinone
Oxidoreductase, also known as the respiratory Complex I (Figure 2-3A).109, 136-138 These
results suggest that Complex I, a protein that catalyzes the first step of oxidative
phosphorylation, is the putative target of thienopyrimidines.107, 139
To further understand the inhibition of H. pylori’s Complex I with the
thienopyrimidine 25, a homology model of the wildtype subunits NuoD and the
neighboring NuoB was generated using Thermus thermophilus’ Complex I as a
template.20 Using Clustal Omega it was found that the NuoB subunit has 59% homology
with T. thermophilus’complex I subunit Nqo6 and 42% homology with T. thermophilus’
complex I subunit Nqo4. The T400I and A402P mutations in NuoD are found in the
quinone binding pocket indicating the thienopyrimidine series bind in this pocket. In
order to visualize the possible binding, the chiral thienopyrimidine 26 was docked into
the known menaquinone binding pocket at the NuoB-NuoD interface (Figure 2-3B). This
model suggests that thienopyrimidine 26 forms a hydrogen bond with the backbone of
T400 and suggests the small molecule inhibits menaquinone binding. In support of the
computational studies, the thienopyrimidine 26 IC50 data shows toxicity to both wild type
and the A402P mutant H. pylori. Further details of the target identification studies and
the homology modeling are provided in the Experimental section of chapter II. To
validate that the thienopyrimidines are on target, all analogs were tested against the
mutant H. pylori strain (SS1 nuoD A402P). The IC50 values against the mutant strain are
provided in Tables A-1 and A-2. The thienopyrimidines are found generally inactive
against the mutant strain, further supporting that Complex I is the target of the series.
Given compound 25 demonstrates high in vitro potency (H.p. IC50 = 0.006 μg/ml,
Table 2-3), we evaluated the in vitro ADME and in vivo pharmacokinetic properties.22-24
The results of these studies are provided in Tables A-3 and A-4, respectively. Compound
25 showed good microsomal stability (t1/2 = 3.8 hr) and permeability (Ave Pe = 239.5 x
10-6 cm/s) but it is highly bound to human plasma protein (HPPB % = 99). 25 showed
good in vivo exposure (AUC = 31907.71 hr*ng/mL, Table A-3) at 50 mg/kg, i.p. dose.
The drug concentration of 25 in the plasma was above its IC50 value for more than 8
hours. With good plasma exposure and cytotoxicity profile, we proceeded to test 25 in the
H. pylori murine infection model.133,134 Further details are provided in (Figure A-1).
Compared to the BMT (Bismuth, Metronidazole and Tetracycline) triple therapy as
control, 25 did not show efficacy at 50 mg/kg (OG), 50 mg/kg (i.p) or 25 mg/kg (i.p).135
To investigate the lack of in vivo efficacy, we tested compound 25 in the ex vivo model of
H. pylori infection. Ten mice were infected with H. pylori SS1 strain and sacrificed after
three days to harvest the stomachs.134,140 In a 12 well plate, one half of each stomach was
placed in Brucella-FBS medium containing compound 25 and the other half was placed
in Brucella-FBS medium only and treated as control. Further details of the ex vivo
experiment are described in the experimental section of chapter II. As described in
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Figure 2-2. Sequence alignment of the wildtype nuoD and two H. pylori mutant
nuoD.
Resistant mutants were generated by exposing H. pylori to compound 25 on agar plate.
Whole genome sequencing was performed, and single nucleotide polymorphism analysis
identified two spontaneous mutants, which had non-synonymous point mutations in
nuoD. The resulting amino acid changes were Threonine to Isoleucine (T400I) and
Alanine to Proline (A402P). nuoD encodes for the subunit D of NADH:Quinone
Oxidoreductase also known as Complex I, a membrane protein that catalyzes the first
step of oxidative phosphorylation. Complex I is the putative target of the
thienopyrimidine.
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Figure 2-3. The homology model of H. pylori’s respiratory Complex I, the
putative target of the thienopyrimidines.
(A) The structure of Complex I with NuoD colored in dark red. The homology model was
generated using the crystal structure of Thermus Thermophilus’ Complex I. The
thienopyrimidines are predicted to bind at the interface of NuoD and NuoB. (B) The lead
compound 26 docked in the proposed binding pocket of Complex 1. The quinone binding
residues are labeled in purple and the substituted amino acids in resistant mutants (T400I
and A402P) against the thienopyrimidine 26 are labeled in blue. According to the
homology model, the changed amino acids are located near the quinone binding pocket,
suggesting 26 inhibits the endogenous quinone from binding to Complex I.
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Figure 2-4, 25 substantially eradicates H. pylori, with 6 stomachs found below the limit
of detection (Figure 2-4). Compound 25 eradicates H. pylori in the ex vivo settings but
does not show in vivo efficacy. This discrepancy suggests that not enough of 25 is getting
to the site of infection and the optimization of the pharmacokinetic properties is required
for the series to demonstrate in vivo efficacy.
Conclusion
In conclusion, we have synthesized 27 analogs and established the anti-H. pylori
SAR at the 4, 5 and 6 position of the thienopyrimidine core. These efforts have generated
potent compounds, including the lead compound 25, with the IC50 of 0.006 μg/mL.
Although 25 does not show in vivo efficacy, it eradicates H. pylori in the ex vivo model.
The mode of action studies identified H. pylori’s respiratory Complex I as the putative
target of the thienopyrimidines, with the amino acid changes found in the NuoD subunit.
Complex I is located in the plasma membrane of bacteria and it catalyzes the first step of
oxidative phosphorylation. Targeting oxidative phosphorylation has been done safely in
the clinic, as exemplified by metformin, a drug used for the treatment of diabetes.141
Additionally, targeting oxidative phosphorylation is becoming an attractive approach in
the treatment of relapsed/refractory AML and solid tumors.142 Recent knockout
mutagenesis studies suggest that nuoD is an essential gene for H. pylori but not for the
majority of other bacteria, indicating that H. pylori can be targeted selectively without
perturbation the host microbiota. 16,31 These examples suggest that Complex I is a
worthwhile target in eradicating H. pylori. 25 is a promising lead compound that is worth
further optimization to realize in vivo efficacy in the H. pylori infected mouse model.
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Figure 2-4. Compound 25 eradicates H. pylori in the ex vivo efficacy experiment.
Ten mice were infected with H. pylori. After 3 days, stomachs were harvested and cut in
half. In a 12 well plate, one half was placed in Brucella-FBS medium and the other half
in Brucella-FBS medium with 0.6 μg/mL of compound 25. After incubation and
homogenization, diluted samples were plated for colony counting. 25 eradicates H. pylori
to below the limit of detection in 6 stomachs.
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CHAPTER 3.

ADME OPTIMIZATION OF THE THIENOPYRIMIDINES
AGAINST HELICOBACTER PYLORI
Introduction

The rate of successful treatment of H. pylori infections, with the clarithromycin
triple therapy, is around 75%.1 The triple therapy, which consists of a proton pump
inhibitor and two broad-spectrum antibiotics such as clarithromycin and amoxicillin, is
increasingly becoming ineffective due to the rise of resistance to these antibiotics.26,27,31
The World Health Organization lists H. pylori as a high priority drug resistant
bacterium.7 In a recent study, 22% of patients tested were not cured by either the triple
therapy or the quadruple therapy with Bismuth added.27 The triple therapy is also
associated with poor patient compliance due to side effects such as diarrhea, derived from
the effect of these broad-spectrum antibiotics on the host microbiota.11 Therefore, a
novel, narrow-spectrum drug is needed for the treatment of H. pylori infections, to
address the challenges of drug resistance against anti-H. pylori drugs and their side
effects.
Advances in whole genome sequencing and highthrough-put screening
approaches have provided opportunities to discover novel chemical matter against H.
pylori. We have previously reported a series of thienopyrimidines that were developed
from two hits, discovered through a high through-put screen of 219,197 compounds.
Subsequent structure-activity relationship studies of the thienopyrimidines against H.
pylori, compound 25 (Figure 3-1A) emerged with a high potency (H. pylori IC50= 0.006
μg/mL) and tolerable cytotoxicity against the human FaDu cells (Cytotox IC50 = 131
μg/mL). Mode of action studies with the lead compound 25 were performed by the
generation and sequencing of resistant mutants. These studies revealed the respiratory
Complex I as the putative target of the series, with amino acid changes found in the
NuoD subunit. NuoD has been previously identified as the target of a series of the
benzimidazole compounds by researchers at AstraZeneca and it was found to be essential
for H. pylori but not for most of bacteria including E. coli.105,106 Therefore, NuoD is an
attractive target, in eradicating H. pylori while preserving the gut microbiota. Complex I,
also known as NADH:Quinone Oxidoreductase, catalyzes the first step of oxidative
phosphorylation.139
The lead compound 25 eradicates H. pylori in the ex vivo model of H. pylori
infection. However, 25 lacked in vivo efficacy in the H. pylori murine model at 50 mg/kg
by oral gavage; suggesting that further optimization of pharmacokinetic properties of the
series is required. An examination of the in vivo pharmacokinetic properties, 25 shows
good exposure (AUC: 31,907 hr*ng/mL at 50 mg/kg OG, Figure 3-1A) and a long high
half-life in liver microsomes (t1/2 = 3.8 hr, Figure 3-1A) suggesting that hepatic
metabolism was not the limiting factor. However, 25 demonstrates a relatively high
volume of distribution (Vss = 6.28 L, Figure 3-1A), suggesting 25 is being trapped in
fatty tissues despite good exposure.145 25 also shows poor solubility (Sol: 0.1 μM,
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Figure 3-1. Lead compound 25 and targeted moieties to improve the ADME
properties.
(A) ain vivo pharmacokinetic properties of 25 at 50 mg/Kg i.p. and bADME properties of
25. (B) Chemical modifications on targeted moieties of 25, to improve the ADME
properties of the series.
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Figure 3-1A) and is highly bound to plasma protein (HPPB% = 99.3, Figure 3-1A),
reducing the amount of free drug able to reach the site of infection. These limitations are
compounded by the hard to reach biological niche of H. pylori, found in the glands of the
stomach and in the mucus layer.
To tackle these shortcomings, in this chapter we look to introduce chemical
modifications that will reduce the lipophilicity and increase the solubility while
maintaining selective anti-H. pylori activity and resistance to hepatic metabolism of 25.
In this chapter we explore the optimization of 25 through targeted synthesis and
examination of the anti-H. pylori activity and ADME properties of four subseries (Figure
3-1B): (i) We replace metabolically labile and solubility limiting phenyl ring substituted
at the 6-poisition of the thienopyrimidine scaffold with pyridinyl, pyrazolyl and methyl
motifs; (ii) Through a scaffold hopping exercise, the introduction of core modifications to
improve the solubility and reduce the tendency of drug to bind to plasma protein are
examined;149 (iii) The introduction of primary amine motif to the side chain of 25,
increase Gram-negative drug entry and increase the distribution in the body fluids is also
tested;146,147 (iv) to reduce drug clearance and compensate for changes elsewhere in the
ring, introduce blocking modifications such as para-fluoro-substitution of the 6-phenyl
ring of the thienopyrimidine core are also examined. 148 Through analysis of the
microbiological and pharmacological properties of the new analogs, new lead candidates
have emerged suitable for further evaluations.
Materials and Methods
Synthesis of Amine 46
tert-butyl (2-hydroxy-1-(4-methoxyphenyl)ethyl)carbamate (60). Di-tert-butyl
dicarbonate (0.447 g, 2.047 mmol) was added to a solution of 2-hydroxy-1-(4methoxyphenyl)ethan-1-aminium chloride 59 (0.347 g, 1.706 mmol) and triethylamine
(0.286 mL, 2.047 mmol) in DCM (5.6 mL). The reaction mixture was stirred for 2 h at
room temperature. The mixture was concentrated and purified by flash column
chromatography (Isolera 1, Biotage, 10 g size, elution gradient 12-80% ethyl acetate in
hexanes). Pure fractions were evaporated to afford 60 as a white solid.
tert-butyl (2-(1,3-dioxoisoindolin-2-yl)-1-(4-methoxyphenyl)ethyl)carbamate
(61). DIAD (0.141 mL, 0.729 mmol) was added dropwise at room temperature, to a
solution of 60 ( 0.150 g, 0.561 mmol), phthalimide (0.107 g, 0.729 mmol) and Ph3P
(0.191 g, 0.729 mmol) in THF (.6 mL). The resulting mixture was stirred for 16 h at room
temperature. The mixture was extracted with Ethyl Acetate/Water and the organic phase
was washed with brine, dried (Na2SO4) and evaporated in vacuo. The residue was
purified by flash column chromatography (Isolera 1, Biotage, 10 g size, elution gradient
12-60% ethyl acetate in hexanes), to afford 61 as a yellow solid.
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2-(2-amino-2-(4-methoxyphenyl)ethyl)isoindoline-1,3-dione (62) and 2-(2-(4methoxyphenyl)-2-((6-phenylthieno[2,3-d]pyrimidin-4-yl)amino)ethyl)isoindoline-1,3dione (63). HCl (4 M in 1,4-dioxane, 0.9 mL, 3.6 mmol) was added to a solution of 61
(0.300 g, 0.757 mmol) in a mixture of DCM (2 mL) and methanol (1 mL), and the
resulting mixture was stirred for 16 h at room temperature. The mixture was subjected to
acid-base extraction with Ethyl Acetate/Water and the organic phase was washed with
brine, dried (Na2SO4) and concentrated in vacuo. The resulting residue 62 (yellow oil)
was used in the next step without further purification. 63 was synthesized following the
general procedure for amination of 4-chloro-6-phenylthieno[2,3-d]pyrimidine.
1-(4-methoxyphenyl)-N1-(6-phenylthieno[2,3-d]pyrimidin-4-yl)ethane-1,2diamine (46). Compound 63 ( 0.130 g, 0.257 mmol) was dissolved in methanol and a 80
% hydrazine hydrate solution (0.04 mL, 0.642 mmol) was added dropwise to the solution
at 0˚C. The reaction mixture was stirred for 16 h at room temperature. The mixture was
extracted with Ethyl Acetate/Water and the organic phase was washed with brine, dried
(Na2SO4) and evaporated in vacuo. The residue was purified by flash column
chromatography (Isolera 1, Biotage, 10 g size, elution gradient 2-20 % methanol in ethyl
acetate) to afford 46 as a white solid.
1-(4-methoxyphenyl)-N1-(6-phenylthieno[2,3-d]pyrimidin-4-yl)ethane-1,2diamine (46). 1H NMR (DMSO, 400 MHz) δ 8.32 (d, J = 0.7 Hz, 1H), 8.03 (s, 1H), 7.77
– 7.67 (m, 2H), 7.51 (dd, J = 8.3, 7.0 Hz, 2H), 7.45 – 7.35 (m, 3H), 6.97 – 6.88 (m, 2H),
5.65 (dd, J = 10.6, 4.4 Hz, 1H), 3.70 (s, 3H), 3.32 (dd, J = 13.1, 10.6 Hz, 1H), 3.23 (dd, J
= 13.1, 4.5 Hz, 1H). MS (ESI): m/z 377 (M++H).
Synthesis of Thienopyrimidine Analog 45
45 was synthesized following the general procedure for amination of 4-chloro-6phenylthieno[2,3-d]pyrimidine.
(R)-3-(4-methoxyphenyl)-3-((6-phenylthieno[2,3-d]pyrimidin-4yl)amino)propan-1-ol (45). 1H NMR (DMSO, 400 MHZ): δ 8.27 (d, J = 4.1 Hz, 1H),
8.19 – 8.11 (m, 2H), 7.74 – 7.64 (m, 2H), 7.52 (q, J = 6.4, 6.0 Hz, 2H), 7.41 (d, J = 8.8
Hz, 1H), 7.36 – 7.30 (m, 2H), 6.91 – 6.84 (m, 2H), 5.46 (d, J = 7.7 Hz, 1H), 4.56 (t, J =
4.7 Hz, 1H), 3.71 (d, J = 3.2 Hz, 2H), 3.46 (dd, J = 13.0, 6.6 Hz, 2H), 2.09 (d, J = 5.1 Hz,
1H), 2.01 – 1.86 (m, 1H); MS (ESI): m/z 392.3 (M++H).
Synthesis of Primary Amine 47
Benzyl (R)-(3-hydroxy-1-(4-methoxyphenyl)propyl)carbamate (65). Benzyl
chloroformate chloride (226 μL, 1.584 mmol) was added to a solution of 64 (261 mg,
1.440 mmol) and trimethylamine (0.504 mL, 3.60 mmol) in THF (7 mL). The reaction
mixture was stirred for 14 h at room temperature. The reaction was concentrated and
extracted with ethyl acetate and water. The organic phase was washed with brine, dried
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(Na2SO4) and evaporated in vacuo. The residue was purified by flash column
chromatography (Isolera 1, Biotage, 10 g size, elution gradient 12-60% ethyl acetate in
hexanes), to afford 65 as a white solid.
Benzyl (R)-(3-(1,3-dioxoisoindolin-2-yl)-1-(4-methoxyphenyl)propyl)carbamate
(66). DIAD (152 mL, 0.785 mmol) was added dropwise at room temperature, to a
solution of 65 (0.225 g, 0.7135 mmol), phthalimide (0.115 g, 0.785 mmol) and Ph3P
(0.206 g, 0.785 mmol) in THF (3.5 mL). The resulting mixture was stirred for 16 h. The
mixture was extracted with ethyl acetate/water and the organic phase was washed with
brine, dried (Na2SO4) and evaporated in vacuo. The residue was purified by flash column
chromatography (Isolera 1, Biotage, 10 g size, elution gradient 12-60 ethyl acetate in
hexanes), to afford 66 as a yellow solid.
Benzyl (R)-(3-amino-1-(4-methoxyphenyl)propyl)carbamate (67). Compound 66
(0.317 g, 0.713 mmol) was dissolved in methanol and a 80 % hydrazine hydrate solution
(0.109 mL, 1.783 mmol) was added dropwise to the solution at 0˚C. The reaction mixture
was stirred for 16 h at room temperature. The mixture was subjected to acid-base
extraction with ethyl acetate/water and the organic phase was washed with brine, dried
(Na2SO4) and concentrated in vacuo. The resulting residue 67 (colorless oil) was used in
the next reaction without further purification.
Benzyl (R)-(3-(((l1-methyl)(l1-oxidaneyl)boraneyl)amino)-1-(4methoxyphenyl)propyl)carbamate (68). Di-tert-butyl dicarbonate (0.143 g, 0.657 mmol)
was added to a solution of 67 (0.172 g, 0.547 mmol) and trimethylamine (0.153 mL,
1.094 mmol) in DCM (3 mL). The reaction mixture was stirred for 2 h at room
temperature. The mixture was extracted with ethyl acetate/water and the organic phase
was washed with brine, dried (Na2SO4) and concentrated in vacuo. The residue 68 was
used in the next step without further purification.
(R)-N1-((l1-methyl)(l1-oxidaneyl)boraneyl)-3-(4-methoxyphenyl)propane-1,3diamine (69). Pd/C (0.200 g, 10% wet) was added to a solution of 68 (0.137 g, 0.331
mmol) in methanol (8 mL). The reaction was stirred under hydrogen for 3h at room
temperature. The mixture was filtered, and the filtrate was concentrated in vacuo. The
residue 69 was used in the next step without further purification.
(R)-N3-((l1-methyl)(l1-oxidaneyl)boraneyl)-1-(4-methoxyphenyl)-N1-(6phenylthieno[2,3-d]pyrimidin-4-yl)propane-1,3-diamine (70). 4-chloro-6-phenylthienopyrimidine 7 (0.45 g, 0.168 mmol), amine 69 (0.61 g, 0.218 mmol), and
triethylamine (0.36 mL, 0.254 mmol) were dissolved in ethanol and the mixture was
heated at 115 ˚C for 14h. The mixture was extracted with ethyl acetate/water and the
organic phase was washed with brine, dried (Na2SO4) and concentrated in vacuo. The
residue was purified by column chromatography (Isolera 1, Biotage, 10 g size, elution
gradient of 12-60% ethyl acetate in hexanes) to afford 70 as a yellow solid.
(R)-1-(4-methoxyphenyl)-N1-(6-phenylthieno[2,3-d]pyrimidin-4-yl)propane-1,3diamine (47). HCl (4M in 1,4-dioxane, 0.073 mL, 0.292 mmol) was added to a solution
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of 70 (0.053 g, 0.215 mmol) in a mixture of DCM (1 mL) and methanol (0.4 mL), and the
resulting mixture was stirred for 16h at room temperature. The mixture was extracted
with ethyl acetate/water and the organic phase was washed with brine, dried (Na2SO4)
and evaporated in vacuo to afford 47 as a yellow solid.
(R)-1-(4-methoxyphenyl)-N1-(6-phenylthieno[2,3-d]pyrimidin-4-yl)propane-1,3diamine (47). 1H NMR (DMSO, 500 MHZ): δ 8.41 (s, 1H), 8.32 (s, 1H), 8.11 (s, 1H),
7.73 (d, 2H, J = 8.1 Hz), 7.53 (t, 2H, J = 7.45 Hz), 7.45-7.39 (m, 2H), 6.93 (d, 2H, J =
8.75 Hz), 5.45-5.43 (m, 1H), 4.79-4.76 (m, 2H), 3.73 (s, 3H), 2.97-2.89 (m, 1H), 2.792.75 (m, 1H), 1.21-1.18 (m, 2H); MS (ESI): m/z 391 (M++H).
Synthesis of Amine 48
Tert-butyl (R)-(3-hydroxy-1-(4-methoxyphenyl)propyl)carbamate (71). Di-tertbutyl dicarbonate (1.98 g, 9.10 mmol) was added to a solution of 64 (1.5 g, 8.28 mmo)
and trimethylamine (1.27 mL, 9.10 mmol) in DCM (40 mL). The reaction mixture was
stirred for 2 h a room temperature. The mixture was concentrated and purified by flash
column chromatography (Isolera 1, Biotage, 10 g size, elution gradient 12-80% ethyl
acetate in hexanes) to afford 71 as a white solid.
(R)-3-((tert-butoxycarbonyl)amino)-3-(4-methoxyphenyl)propyl
methanesulfonate (72). Methanesulfonyl chloride (0.825 mL, 10.66 mmol) was added to
a solution of 71 (1 g, 3.55 mmol) and trimethylamine (1.487 mL, 10.66 mmol) at 0˚C.
The reaction mixture was stirred for 3h at room temperature. The mixture was
concentrated and purified by flash column chromatography (Isolera 1, Biotage, 10 g size,
elution gradient 12-80% ethyl acetate in hexanes) to afford 72 as a yellow solid.
Tert-butyl (R)-(3-(dimethylamino)-1-(4-methoxyphenyl)propyl)carbamate (73).
In a microwave tube, compound 72 (0.075 g, 0.21 mmol) and tetrabutylammonium (0.01
g, 0.042 mmol) were dissolved with dimethylamine (2M in THF, 2 mL) and subjected to
microwave heating at 150˚C for 0.5 h. The mixture was extracted with ethyl acetate/water
and the organic phase was washed with brine, dried (Na2SO4) and concentrate in vacuo.
The resulting residue 73 (bright red oil) was used in the next step without further
purification.
(R)-1-(4-methoxyphenyl)-N3,N3-dimethylpropane-1,3-diamine (74). HCl (4 M
in 1,4-dioxane, 0.422 mL, 1.688 mmol) was added to a solution of 73 (0.13 g, 0.422
mmol) in a mixture of DCM (2 mL) and methanol (0.8 mL) , and the resulting mixture
was stirred for 16h at room temperature. The mixture was subjected to acid-base
extraction with ethyl acetate/water and the organic phase was washed with brine, dried
(Na2SO4) and concentrated in vacuo. The resulting residue 74 (colorless oil) was used in
the next step without further purification.
(R)-1-(4-methoxyphenyl)-N3,N3-dimethyl-N1-(6-phenylthieno[2,3-d]pyrimidin4-yl)propane-1,3-diamine (48). 4-Chloro-6-phenyl-thienopyrimidine 7 (0.048 g, 0.195
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mmol), amine 74 (0.05 g, 0.204 mmol), and triethylamine (0.056 mL, 0.408 mmol) were
dissolved in ethanol and the mixture was heated at 115 ˚C for 14h. The mixture was
extracted with ethyl acetate/water and the organic phase was washed with brine, dried
(Na2SO4) and concentrated in vacuo. The residue was purified by column
chromatography (Isolera 1, Biotage, 10 g size, elution gradient of 0-20% methanol in
ethyl acetate) to afford 48 as yellow solid.
(R)1-(4-methoxyphenyl)-N3,N3-dimethyl-N1-(6-phenylthieno[2,3-d]pyrimidin4-yl)propane-1,3-diamine (48). 1H NMR (MeOD, 500 MHz) δ 8.27 (d, J = 1.1 Hz, 1H),
7.90 (s, 1H), 7.70 (dt, J = 8.4, 1.7 Hz, 2H), 7.45 (dd, J = 8.5, 7.1 Hz, 2H), 7.41 – 7.34 (m,
3H), 6.92 – 6.88 (m, 2H), 5.44 (t, J = 7.3 Hz, 1H), 3.80 – 3.75 (m, 3H), 2.48 (ddd, J =
12.6, 9.9, 5.3 Hz, 1H), 2.37 (ddd, J = 12.6, 9.9, 6.0 Hz, 1H), 2.28 (s, 6H), 2.21 – 2.09 (m,
2H); MS (ESI): m/z 419 (M++H).
Synthesis of Thienopyrimidine Analog 49
49 was synthesized following the general procedure for the amination 4-chloro-6phenylthieno[2,3-d]pyrimidine.
(R)-3-((6-phenylthieno[2,3-d]pyrimidin-4-yl)amino)-3-(pyridin-4-yl)propan-1-ol
(49). H NMR (MeOD, 500 MHz) δ 8.54 – 8.44 (m, 2H), 8.26 (d, J = 2.7 Hz, 1H), 7.96
(s, 1H), 7.81 – 7.70 (m, 2H), 7.59 – 7.51 (m, 2H), 7.49 (dd, J = 8.5, 7.0 Hz, 2H), 7.44 –
7.37 (m, 1H), 5.65 (dd, J = 9.2, 5.5 Hz, 1H), 3.81 – 3.66 (m, 2H), 2.21 (qdt, J = 13.9, 7.8,
5.5 Hz, 2H); MS (ESI): m/z 363 (M++H).
1

Synthesis of Thienopyrimidine and Pyrrolopyrimidine Analogs with Modifications
at the 6-position
2-((6-bromothieno[2,3-d]pyrimidin-4-yl)amino)-2-(4-methoxyphenyl)ethan-1-ol
(76a). 4-Chloro-6-bromo-thienopyrimdine 75a (0.025 mg, 0.100 mmol), amine 59 (0.050
mg, 0.299 mmol) and trimethylamine (0.042 mL, 0.299 mmol) were dissolved in ethanol
and the mixture was heated at 115 ˚C for 14h. The mixture was extracted with ethyl
acetate/water and the organic phase was washed with brine, dried (Na2SO4) and
concentrated in vacuo. The resulting residue 76a (red solid, with the pyrrolopyrimidine)
was used in the next reaction without further purification.
2-(4-methoxyphenyl)-2-((6-(pyridin-4-yl)thieno[2,3-d]pyrimidin-4yl)amino)ethan-1-ol (50). Compound 76a (0.08 g, 0.210 mmol), tetraphenyl pallidium
(0.005 g, 0.0012 mmol) and compound 77a (0.039 g, 0.316 mmol) were dissolved in
dioxane (4 mL). The solution was bubbled with nitrogen for 15 min. Then, an aqueous
solution of NaHCO3 (0.083 g, 0.993 mmol) was added and the mixture was heated at 75
˚C for 14h. The mixture was extracted with ethyl acetate/water and the organic phase was
washed with brine, dried (Na2SO4) and concentrated in vacuo. The residue was purified
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by column chromatography (Isolera 1, Biotage, 10 g size, elution gradient of 0-20%
methanol in ethyl acetate) to afford 50 as yellow solid.
2-(4-methoxyphenyl)-2-((6-(pyridin-4-yl)thieno[2,3-d]pyrimidin-4yl)amino)ethan-1-ol (50). 1H NMR (MeOD, 400 MHz) δ 8.31 – 8.18 (m, 1H), 8.03 –
7.93 (m, 1H), 7.81 – 7.68 (m, 2H), 7.52 – 7.45 (m, 2H), 7.43 – 7.36 (m, 3H), 6.92 (ddd, J
= 8.5, 3.2, 1.5 Hz, 2H), 5.52 (s, 1H), 3.94 (dd, J = 5.8, 3.5 Hz, 2H), 3.82 – 3.70 (m, 3H);
MS (ESI): m/z 379.4 (M++H).
2-(4-methoxyphenyl)-2-((6-(pyridin-3-yl)thieno[2,3-d]pyrimidin-4yl)amino)ethan-1-ol (51). Compound 76a (0.1 g, 0.263 mmol), tetraphenyl pallidium
(0.005 g, 0.0012 mmol) and compound 77b (0.048 g, 0.394 mmol) were dissolved in
dioxane (4 mL). The solution was bubbled with nitrogen for 15 min. Then, an aqueous
solution of NaHCO3 (0.104 g, 1.238 mmol) was added and the mixture was heated at 75
˚C for 14h. The mixture was extracted with ethyl acetate/water and the organic phase was
washed with brine, dried (Na2SO4) and concentrated in vacuo. The residue was purified
by column chromatography (Isolera 1, Biotage, 10 g size, elution gradient of 0-20%
methanol in ethyl acetate) to afford 51 as yellow solid.
2-(4-methoxyphenyl)-2-((6-(pyridin-3-yl)thieno[2,3-d]pyrimidin-4yl)amino)ethan-1-ol (51). 1H NMR (DMSO, 500 MHz) δ 8.95 (d, J = 2.5 Hz, 1H), 8.60
(dd, J = 4.8, 1.5 Hz, 1H), 8.31 (s, 1H), 8.35 (s, 1H), 8.23 (d, J = 8.0 Hz, 1H), 8.08 (dt, J =
8.0, 2.0 Hz, 1H), 7.40 – 7.32 (m, 2H), 6.93 – 6.86 (m, 2H), 5.41 (td, J = 7.9, 5.3 Hz, 1H),
5.04 (s, 2H), 3.72 (s, 4H); MS (ESI): m/z 379.2 (M++H).
2-(4-methoxyphenyl)-2-((6-(pyridin-2-yl)thieno[2,3-d]pyrimidin-4yl)amino)ethan-1-ol (52). Compound 76a (0.1 g, 0.263 mmol), tetraphenyl pallidium
(0.005 g, 0.0012 mmol) and compound 77c (0.048 g, 0.394 mmol) were dissolved in
dioxane (4 mL). The solution was bubbled with nitrogen for 15 min. Then, an aqueous
solution of NaHCO3 (0.104 g, 1.238 mmol) was added and the mixture was heated at 75
˚C for 14h. The mixture was extracted with ethyl acetate/water and the organic phase was
washed with brine, dried (Na2SO4) and concentrated in vacuo. The residue was purified
by column chromatography (Isolera 1, Biotage, 10 g size, elution gradient of 0-20%
methanol in ethyl acetate) to afford 52 as yellow solid.
2-(4-methoxyphenyl)-2-((6-(pyridin-2-yl)thieno[2,3-d]pyrimidin-4yl)amino)ethan-1-ol (52). 1H NMR (DMSO, 400 MHz) δ 8.95 (d, J = 2.4 Hz, 1H), 8.60
(dd, J = 4.8, 1.5 Hz, 1H), 8.33 (d, J = 12.6 Hz, 2H), 8.20 (d, J = 8.0 Hz, 1H), 8.08 (ddd, J
= 8.0, 2.5, 1.5 Hz, 1H), 7.36 (d, J = 8.6 Hz, 2H), 6.92 – 6.87 (m, 2H), 5.41 (q, J = 7.5 Hz,
1H), 5.02 (t, J = 5.7 Hz, 1H), 3.72 (s, 5H); MS (ESI): m/z 379.4 (M++H).
2-((6-(1H-pyrazol-4-yl)thieno[2,3-d]pyrimidin-4-yl)amino)-2-(4methoxyphenyl)ethan-1-ol (53). Compound 76a (0.1 g, 0.263 mmol), tetraphenyl
pallidium (0.005 g, 0.0012 mmol) and compound 77d (0.044 g, 0.394 mmol) were
dissolved in dioxane (4 mL). The solution was bubbled with nitrogen for 15 min. Then,
an aqueous solution of NaHCO3 (0.104 g, 1.238 mmol) was added and the mixture was
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heated at 75 ˚C for 14h. The mixture was extracted with ethyl acetate/water and the
organic phase was washed with brine, dried (Na2SO4) and concentrated in vacuo. The
residue was purified by column chromatography (Isolera 1, Biotage, 10 g size, elution
gradient of 0-20% methanol in ethyl acetate) to afford 53 as yellow solid.
2-((6-(1H-pyrazol-4-yl)thieno[2,3-d]pyrimidin-4-yl)amino)-2-(4methoxyphenyl)ethan-1-ol (53). 1H NMR (DMSO, 400 MHz) δ 8.22 (d, J = 1.6 Hz, 1H),
8.08 (d, J = 7.9 Hz, 1H), 7.84 (s, 1H), 7.39 – 7.30 (m, 2H), 6.92 – 6.83 (m, 2H), 5.36 (q, J
= 7.8 Hz, 1H), 5.07 (s, 1H), 3.72 (d, J = 1.4 Hz, 5H); MS (ESI): m/z 368.3 (M++H).
Synthesis of Thienopyrimidine Analog 54
54 was synthesized following the general procedure for the amination 4-chloro-6phenylthieno[2,3-d]pyrimidine.
2-((5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)amino)-2-(4-methoxyphenyl)ethan1-ol (54). 1H NMR (CDCl3, 400 MHz) δ 8.33 (s, 1H), 7.35 – 7.28 (m, 2H), 6.92 (dd, J =
8.4, 1.3 Hz, 2H), 6.15 (d, J = 5.8 Hz, 1H), 5.35 (q, J = 5.5 Hz, 1H), 4.06 – 3.96 (m, 2H),
3.81 (d, J = 1.0 Hz, 3H), 2.49 – 2.38 (m, 6H). MS (ESI): m/z 330.01 (M++H).
Synthesis of Fluorophenyl Thienopyrimidine Analog 55
Ethyl 2-amino-5-(4-fluorophenyl)thiophene-3-carboxylate (79). In a microwave
tube, ethyl 3-cyanoacetate 4 (0.693 mL, 6.52 mmol) was added to a solution of 2-(4fluorophenyl)acetaldehyde 78 (0.804 g, 6.52 mmol), sulfur (0.23 g, 7.17 mmol) and
morpholine (0.651 mL, 7.54 mmol) in ethanol (20 mL). The resulting mixture was
submitted to microwave heating for 30 min at 70˚C. After cooling, the mixture was
filtered, and the filtrate was poured in water. The precipitate was collected, dried and
purified by flash column chromatography (Isolera 1, Biotage, 25 g size, elution gradient
12-60% ethyl acetate in hexanes) to afford 79 as a yellow solid.
Ethyl 2-amino-5-(4-fluorophenyl)thiophene-3-carboxylate (79). 1H NMR
(MeOD, 500 MHZ): δ 7.45-7.41 (m, 2H), 7.14 (s, 1H), 7.08-7.03 (m, 2H), 4.58 (s, 2H),
4.30-4.24 (q, 2H, J = 9.05 Hz), 1.37-1.29 (t, 3H, J = 8.95 Hz); MS (ESI): m/z 266
(M++H).
6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4(3H)-one (80). Compound 79 (1.15
g, 4.33 mmol) was dissolved in excess formamide and the resulting mixture was heated
for 16 h at 160˚C. The mixture was concentrated in vacuo and purified by flash column
chromatography (Isolera 1, Biotage, 25 g size, elution gradient 12-60% ethyl acetate in
hexanes) to afford 80 as a red solid.
6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4(3H)-one (80). 1H NMR (DMSO,
500 MHZ): δ 8.41 (s, 1H), 7.85-7.81 (m, 2H), 7.78 (s, 1H), 7.33-7.27 (m, 2H); MS (ESI):
m/z 247 (M++H).
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4-chloro-6-(4-fluorophenyl)thieno[2,3-d]pyrimidine (81). Compound 80 (0.32 g,
0.13 mmol) and N,N-dimethylaniline (0.001 mL, 0.009 mmol) were dissolved in
phosphoryl trichloride (0.5 mL, 8.12 mmol) and the mixture was heated for 16 h to 95˚C.
The mixture was concentrated in vacuo and purified by flash column chromatography
(Isolera 1, Biotage, 25 g size, elution gradient of 12-60% ethyl acetate in hexanes) to
afford 81 as a yellow solid.
4-chloro-6-(4-fluorophenyl)thieno[2,3-d]pyrimidine (81). 1H NMR (CDCl3, 500
MHZ): δ 8.82 (s, 1H), 7.74-7.69 (m, 2H), 7.52 (s, 1H), 7.22-7.16 (m, 2H); MS (ESI): m/z
265 (M++H).
In the last step, 55 was synthesized following the general procedure for the
amination 4-chloro-6-phenylthieno[2,3-d]pyrimidine.
2-((6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)amino)-2-(4methoxyphenyl)ethan-1-ol (55). 1H NMR (CDCl3, 400 MHz) δ 8.45 (s, 1H), 7.66 – 7.59
(m, 2H), 7.35 (d, J = 8.7 Hz, 2H), 7.13 (t, J = 8.6 Hz, 3H), 6.94 (d, J = 8.7 Hz, 2H), 5.72
(d, J = 6.2 Hz, 1H), 5.40 (d, J = 4.0 Hz, 1H), 4.13 – 4.03 (m, 3H), 3.82 (s, 3H); MS (ESI):
m/z 396.2 (M++H).
Synthesis of Pyrrolopyrimidine and Quinazoline Analogs with Modification at the 6position
2-((6-bromo-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-(4methoxyphenyl)ethan-1-ol (76b). 6-Bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimdine 75b
(0.070 mg, 0.301 mmol), amine 59 (0.076 mg, 0.452 mmol) and trimethylamine (0.126
mL, 0.904 mmol) were dissolved in ethanol and the mixture was heated at 115 ˚C for
14h. The mixture was extracted with ethyl acetate/water and the organic phase was
washed with brine, dried (Na2SO4) and concentrated in vacuo. The resulting residue 76b
was used in the next reaction without further purification.
2-(4-methoxyphenyl)-2-((6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4yl)amino)ethan-1-ol (56). Compound 76b (0.081 g, 0.263 mmol), tetraphenyl pallidium
(0.005 g, 0.0012 mmol) and compound 77e (0.039 g, 0.316 mmol) were dissolved in
dioxane (4 mL). The solution was bubbled with nitrogen for 15 min. Then, an aqueous
solution of NaHCO3 (0.083 g, 0.993 mmol) was added and the mixture was heated at 75
˚C for 14h. The mixture was extracted with ethyl acetate/water and the organic phase was
washed with brine, dried (Na2SO4) and concentrated in vacuo. The residue was purified
by column chromatography (Isolera 1, Biotage, 10 g size, elution gradient of 0-20%
methanol in ethyl acetate) to afford 56 as yellow solid.
2-(4-methoxyphenyl)-2-((6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4yl)amino)ethan-1-ol (56). 1H NMR (DMSO, 500 MHz) δ 12.11 (s, 1H), 8.08 (s, 1H),
7.80 (d, J = 7.8 Hz, 2H), 7.45 (t, J = 7.6 Hz, 2H), 7.35 (d, J = 8.3 Hz, 2H), 7.30 (t, J = 7.4

47

Hz, 1H), 7.15 (s, 1H), 6.91 – 6.83 (m, 2H), 5.36 (q, J = 7.4 Hz, 1H), 4.95 (s, 1H), 3.81 –
3.64 (m, 5H); MS (ESI): m/z 361.4 (M++H).
2-((7-bromoquinazolin-4-yl)amino)-2-(4-methoxyphenyl)ethan-1-ol (83). 7bromo-4-chloroquinazoline 82 (0.2 g, 0.821 mmol), amine 59 (0.208 g, 1.232 mmol) and
trimethylamine (0.573 mL, 4.11 mmol) were dissolved in ethanol and the mixture was
subjected to microwave heating at 150 ˚C for 1h. The mixture was extracted with ethyl
acetate/water and the organic phase was washed with brine, dried (Na2SO4) and
concentrated in vacuo. The resulting residue 83 was used in the next reaction without
further purification.
2-(4-methoxyphenyl)-2-((7-phenylquinazolin-4-yl)amino)ethan-1-ol (57).
Compound 83 (0.1 g, 0.267 mmol), tetraphenyl pallidium (0.005 g, 0.0012 mmol) and
phenylboronic acid 77e (0.049 g, 0.401 mmol) were dissolved in dioxane (4 mL). The
solution was bubbled with nitrogen for 15 min. Then, an aqueous solution of NaHCO3
(0.185 g, 1.336 mmol) was added and the mixture was heated at 75 ˚C for 14h. The
mixture was extracted with ethyl acetate/water and the organic phase was washed with
brine, dried (Na2SO4) and concentrated in vacuo. The residue was purified by column
chromatography (Isolera 1, Biotage, 10 g size, elution gradient of 0-100% ethyl acetate in
hexanes) to afford 57 as white solid.
2-(4-methoxyphenyl)-2-((7-phenylquinazolin-4-yl)amino)ethan-1-ol (57). 1H
NMR (DMSO, 500 MHz) δ 8.57 (d, J = 8.6 Hz, 1H), 8.44 – 8.40 (m, 2H), 8.21 (s, 1H),
7.93 – 7.87 (m, 2H), 7.87 – 7.83 (m, 2H), 7.53 (dd, J = 8.3, 7.0 Hz, 2H), 7.48 – 7.43 (m,
1H), 7.40 – 7.34 (m, 2H), 6.90 – 6.85 (m, 2H), 5.48 (td, J = 8.2, 5.2 Hz, 1H), 3.84 (dd, J
= 11.2, 8.6 Hz, 1H), 3.71 (s, 4H). MS (ESI): m/z 372.4 (M++H).
Synthesis of Quinazoline Analog 58
2-((6-bromoquinazolin-4-yl)amino)-2-(4-methoxyphenyl)ethan-1-ol (81). 6bromo-4-chloroquinazoline 75c (0.200 g, 0.821 mmol), amine 59 (0.208 g, 1.232 mmol)
and trimethylamine (0.573 mL, 4.11 mmol) were dissolved in ethanol and the mixture
was subjected to microwave heating at 150 ˚C for 1h. The mixture was extracted with
ethyl acetate/water and the organic phase was washed with brine, dried (Na2SO4) and
concentrated in vacuo. The resulting residue 76c was used in the next reaction without
further purification.
2-(4-methoxyphenyl)-2-((6-phenylquinazolin-4-yl)amino)ethan-1-ol (58).
Compound 76c (0.1 g, 0.267 mmol), tetraphenyl pallidium (0.005 g, 0.0012 mmol) and
phenylboronic acid 77e (0.049 g, 0.401 mmol) were dissolved in dioxane (4 mL). The
solution was bubbled with nitrogen for 15 min. Then, an aqueous solution of NaHCO3
(0.185 g, 1.336 mmol) was added and the mixture was heated at 75 ˚C for 14h. The
mixture was extracted with ethyl acetate/water and the organic phase was washed with
brine, dried (Na2SO4) and concentrated in vacuo. The residue was purified by column
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chromatography (Isolera 1, Biotage, 10 g size, elution gradient of 0-100% ethyl acetate in
hexanes) to afford 58 as yellow solid.
2-(4-methoxyphenyl)-2-((6-phenylquinazolin-4-yl)amino)ethan-1-ol (58). 1H
NMR (500 MHz, DMSO) δ 8.77 (d, J = 2.1 Hz, 1H), 8.53 (d, J = 7.9 Hz, 1H), 8.40 (s,
1H), 8.15 (s, 1H), 8.11 (dd, J = 8.6, 2.0 Hz, 1H), 7.92 – 7.82 (m, 2H), 7.78 – 7.71 (m,
1H), 7.56 (t, J = 7.8 Hz, 2H), 7.44 (dd, J = 8.2, 6.5 Hz, 1H), 7.41 – 7.32 (m, 2H), 6.93 –
6.82 (m, 2H), 5.51 (td, J = 8.2, 5.2 Hz, 1H), 5.02 (s, 1H), 3.85 (dd, J = 11.2, 8.6 Hz, 1H),
3.81 – 3.61 (m, 4H); MS (ESI): m/z 372.3 (M++H).
Results and Discussion
Chemistry
The synthesis of the amine compounds 46 and 31 (was carried out as described in
Scheme 3-1. Starting from the amino-2-(4-methoxyphenyl)ethan-1-ol 59, Boc-protection
of the free amine gave alcohol 60. Mitsunobu conditions were then used to introduce the
targeted terminal amine as a phthalimide group to afford the intermediate 61. After Bocdeprotection with HCl, 62 was reacted with 4-chloro, 6 phenyl thienopyrimidine 62 to
give the substituted thienopyrimidine 63, deprotection of the phthalimide group in the
presence of hydrazine afforded 46. The second targeted amine, compound 47, was
synthesized using a similar strategy as described in Scheme 3-2. Starting from (R)-3amino-3-(4-methoxyphenyl)propanol 64, amine protection with the benzyl chloroformate
afforded 65. Then, a phthalimide group was again introduced under mitsonubu
conditions, to yield intermediate 66. Cbz-protection of the (R)-3-amino-3-(4methoxyphenyl)propanol 64 , from the previous step, prevents the attack of amine to the
ketone of the phthalimide group that results in the cyclized side product. Deprotection of
the phthalimide and subsequent protection of the free amine 67 with di-tert-butyl
dicarbonate gave compound 68. Deprotection reaction of benzyl chloroformate (Cbz)
yielded amine 69, which was coupled to 4-chloro, 6-phenylthienopyrimidine 7 to afford
70. The targeted amine compound 47 was achieved following the final Boc-deprotection
reaction of 70 in the presence of HCl.
To examine the SAR of 47, the dimethyl amine analog of 47, 48, was generated
Scheme 3-3. Starting from (R)-3-amino-3-(4-methoxyphenyl)propanol 64, Bocprotection of the free amine gave compound 71. Then, mesylation of alcohol group with
mesylchloride afforded the intermediate 72. Displacement of the mesylate group with
dimethylamine in THF gave tertiary amine intermediate 73. Acid catalyzed deprotection
yielded the free amine 74, which was coupled to 4-chloro, 6-phenyl, thienopyrimidine to
afford the targeted compound 48. To replace the para methoxy phenyl moiety of 25, with
a less lipophilic, pyridinyl ring, compounds 49 was synthesized following the general
procedure for the amination of 4-chloro, 6-phenyl, thienopyrimidine. Next synthetic
efforts aimed to diminish the lipophilicity by substitution to phenyl ring at the 6 position
of the thienopyrimidine. Pyridyl and pyrazolyl analogs were synthesized as described in
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Scheme 3-1. Synthesis of amine 46.

Reagents and Conditions: (i) di-tert-butyl decarbonate, Et3N, DCM, RT, 2 h; (ii)
Phthalimide, DIAD, Ph3P, DCM, RT, 4h; (iii) 4 M HCl in dioxane, DCM, methanol, RT,
4 h; (iv) Et3N, reflux, 6 h; (v) NH2NH2, methanol, RT, 6 h.
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Scheme 3-2. Synthesis of the primary amine 47.

Reagents and conditions: (i) Benzyl chloroformate, Et3N, THF, RT, 14 h; (ii)
Phthalimide, DIAD, Ph3P, DCM, RT, 4h; (iii) NH2NH2, methanol, RT, 6 h; (iv) di-tertbutyl decarbonate, Et3N, DCM, RT, 2 h; (v) Pd/C (10 wt%), H2, methanol, 14 h; (vi)
Et3N, reflux, 6 h; (vii) 4 M HCl in dioxane, DCM, methanol, RT, 4 h.
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Scheme 3-3. Synthesis of amine 48.

Reagents and conditions: (i) di-tert-butyl dicarbonate, Et3N, DCM, RT, 2 h; (ii)
Methanesulfonyl chloride, Et3N, DCM, RT, 2 h; (iii) Dimethylamine in ethanol,
tetrabutylammonium, 150˚C, Microwave, 0.5 h; (iv) 4 M HCl in dioxane, DCM, methanol,
RT, 4 h; (v) Ethanol, 150˚C, Microwave, 1 h.
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Scheme 3-4. Starting from 4-chloro, 6-bromo thienopyrimidine, amination reaction
introduced the 4-position side chain and gave the intermediate 76. Suzuki coupling
reaction of 76 with the corresponding aryl boronic acids gave the targeted compounds 5053. To remove the 6-phenyl ring and replace it with a methyl motif, 54 was synthesized
following the general procedure for the amination of 4-chloro, 6-phenyl
thienopyrimidine.
To improve drug clearance of next generation compounds fluorination was
explored. Compound 55 was synthesized with a fluorine atom at the para position of the
6-phenyl moiety, as described in Scheme 3-5. Starting with fluoro-phenylacetaldehyde
82, we carried out ring closure to give the fluorophenylthiophene 83 in the presence of
ethyl-3-cyanopropanoate 4. The pyrimidine 84 was formed by heating a solution of
compound 83 in excess formamide. Chlorine substituted thienopyrimidine 85 was
prepared in the presence of phosphoryl chloride and was coupled with the amine 59 to
give the targeted analog 55.
In a scaffold hopping exercise, to replace the sulfur atom and decrease the
lipophilicity and increase the stability of 25, pyrrolopyrimidine and quinazoline scaffolds
were identified.134 Compounds 56 and 58 (ClogP: 3.73 and 4.18, respectively) were
synthesized as described in Scheme 3-4. Compound 57 (ClogP: 4.18) was synthesized as
described in Scheme 3-6. First, we carried out amination of compound 82 to give the
intermediate 83. Then a Suzuki coupling reaction was prepared with 83 and the boronic
acid 77e to yield targeted compound 57.
Anti-H. pylori Activity of New Analogs
Amine Series. Primary amine compounds 46 and 47 did not show anti-H. pylori
activity (H.p. IC50 of 2.1 and 2.1 μg/mL respectively, Table 3-1) compared to their
corresponding alcohols 25 and 45 (H.p. IC50 of 0.006 and 0.08 μg/mL respectively,
Table 3-1). Fluorination to the side chain phenyl ring produced primary amine 31, which
showed slightly improved activity and therapeutic index (H.p. IC50: 0.54 μg/mL and T.
Index: 35.43). The tertiary amine 48 further weakened activity (H.p. IC50: 12.9 μg/mL).
To reduce lipophilicity, compound 49 (ClogP = 3.17, Table 3-1) was synthesized to
replace the para methoxy phenyl motif of 25, with a pyridinyl ring.Compound 49 showed
activity but was cytotoxic, resulting in a low therapeutic index (H.p. IC50: 0.167 μg/mL
and T. Index: 92.39, Table 3-1).
Heteroaryl Substitution. Pyridinyl substitution at the 6- position
theinopyrimidine was well tolerated. 50, 51 and 52 show good anti-H. pylori activities
(IC50: 0.112 μg/mL, 0.084 μg/mL and 0.115 μg/mL respectively, Table 3-2). However,
these compounds are cytotoxic, and demonstrate low therapeutic indices (T. Index: 55.80,
169.17 and 95.91 respectively, Table 3-2). Compound 53 with a pyrazole ring at the 6position, was less potent and more cytotoxic than the corresponding pyridines (H.p. IC50:
0.385 μg/mL, Cytotox IC50: 6.31 μg/mL, Table 3-2). The pyridyl and pyrazole decreased
the LogP of the series by over one Log unit, suggesting a major increase in solubility.
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Scheme 3-4. Synthesis of thienopyrimidine and pyrrolopyrimidine derivatives with
modifications at the 6-position.

Reagents and conditions: (i) Ethanol, 150˚C, Microwave, 1 h; (ii) Pd(Ph)4, K2CO3,
Dioxane, 70˚C, 14 h.

Scheme 3-5. Synthesis of fluorophenyl thienopyrimidine 55.

Reagents and conditions: (i) Sulfur, Morpholine, Ethanol, 70˚C, Microwave, 20 min,
90%; (ii) Formamide, reflux, 18 h, 80%; (iii) POCl3, N,N dimethylaniline, reflux, 14 h,
90%; (iv) Ethanol, 150˚C, Microwave, 1 h, 93%.
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Scheme 3-6. Synthesis of quinazoline 57.

Reagents and conditions: (i) Ethanol, 150˚C, Microwave, 1 h; (ii) Pd(Ph)4, K2CO3,
Dioxane, 70˚C, 14 h.
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Table 3-1.
Thienopyrimidines with modified moieties at the 4-position for
improved solubility and reduced lipophilicity.
Compound

Structure

ClogP

H. pylori
IC50
[μg/mL]
SS1
strain

25

4.23

0.006

200

33,333.33

30

4.31

0.004

12.42

3105

45

4.59

0.077

15.63

202.98

46

4.30

2.1

16.06

7.64

31

4.38

0.538

19.06

35.43

56

Cytotoxicity Therapeutic
IC50
Index
[μg/mL]
FaDu Cells

Table 3-1.
Compound

(Continued).
Structure

ClogP H. pylori Cytotoxicity
IC50 [μg/mL]
IC50
[μg/mL] FaDu Cells
SS1
strain

Therapeutic
Index

47

4.67

2.09

43.75

20.93

48

5.51

12.92

15.72

1.22

49

3.17

0.167

15.43

92.39
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Table 3-2.
Compound

Thienopyrimidines with modifications at the 4-position.
Structure

ClogP

H. pylori Cytotoxicity Therapeutic
Index
IC50
IC50
[μg/mL]
[μg/mL]
SS1
FaDu Cells
strain

50

2.75

0.112

6.25

55.80

51

2.75

0.084

14.21

169.17

52

2.96

0.115

11.03

95.91

53

2.36

0.385

6.31

16.39

54

3.08

0.123

34.87

283.49

55

4.37

0.016

200

12,500
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To reduce lipophilicity, we synthesized compound 54 (ClogP: 3.08, Table 3-2)
with a methyl group replacing the phenyl ring at the 6-position. Compound 54 shows
acceptable activity and a good therapeutic index (H.p. IC50: 0.123 μg/mL, T. Index:
283.49 μg/mL).
Fluorination of Leads. Compound 55, with a fluorine substituted at the 6-phenyl
ring, maintained high potency (H.p. IC50: 0.016 μg/mL, Table 3-2) and an excellent
therapeutic window. (T. Index: 12,500, Table 3-2).
Scaffold Hopping Analogs. The pyrrole-pyrimidine compound 56 (H.p. IC50:
0.065 μg/mL, Table 3-3) and the quinazoline compound 57 (H.p. IC50: 0.034 μg/mL,
Table 3-3) demonstrate high potency and acceptable therapeutic indices (T. Index:
454.31 and 730 respectively, Table 3-3). The quinazoline 58 shows reduced potency
(H.p. IC50: 0.499 μg/mL, Table 3-3), suggesting the phenyl ring is preferred at the 7position over the 6-position of the quinazoline core.
ADME Properties of New Leads
Since, compounds 30, 45, 54, 55, 56 and 57 demonstrate good therapeutic indices
(> 200), we proceeded to determine the solubility, the human plasma protein binding
percentage and the microsomal stability of these compounds (Table 3-4). Compared to
25, compound 30 shows a slightly improved solubility (Sol: 3 μM, Table 3-4) and a
reduced metabolic stability (t1/2 = 0.86 hr, Table 3-4). To our surprise, compound 45
show good solubility (Sol: 63.7 μg/mL, Table 3-4), a good HPPB% (96.71, Table 3-4)
and an acceptable metabolic stability (t1/2 = 0.99 hr, Table 3-4). When comparing
compound 25 and 55 (Table 3-4), the introduction of a fluorine atom at the para position
of the 6-phenyl ring, significantly improve the microsomal stability (t1/2: 13.34 hr, Table
3-4) but decreased the solubility. The replacement of the phenyl substituent at the 6
position with a methyl motif, as exemplified by compound 54, significantly improves the
solubility (Sol: 69.8 μM, Table 3-4) and reduces the plasma protein binding (HPPB%:
95.9, Table 3-4). However, this replacement of phenyl with a methyl leads to a major
reduction of metabolic stability (t1/2: 0.03 hr, Table 3-4). The pyrrolopyrimidine analog
56 demonstrates an improved solubility (Sol: 20.1 μM, Table 3-4) and a reduced plasma
protein binding (HPPB%: 97.9, Table 3-4). Although 57 is less bound to plasma protein
(HPPB%: 98.1, Table 3-4), it does not demonstrate a significant improvement in
solubility (Sol: 2.4 μM, Table 3-4).
Conclusion
In conclusion, we have introduced targeted chemical modifications to improve the
in vitro pharmacokinetic properties of the lead compound 25. Although it demonstrates a
high potency (H. p. IC50: 0.006 ug/mL), 25 lacks in vivo efficacy due to poor solubility,
high protein binding and high lipophilicity. These factors limit the amount of free drug
concentration that reaches the H. pylori site of infection. Efforts to improve these in vitro
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Table 3-3.
solubility.
Compound

Pyrrolo[2,3-d]pyrimidine and quinazolines synthesized for improved
Structure

ClogP

H. pylori Cytotoxicity Therapeutic
IC50
IC50
Index
[μg/mL]
[μg/mL]
SS1
FaDu Cells
strain

56

3.73

0.065

29.53

454.31

57

4.18

0.034

24.82

730

58

4.18

0.499

32

64.13
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Table 3-4.

ADME properties of selected compounds.

ClogP

H. p.
IC50
[μg/mL]

Cytotox
FaDu
Cell
[μg/mL]

Solubility
[μM]

Human
Plasma
Binding
(%)

Mouse
Microsomal
Stability t1/2
[hr]

25

4.23

0.006

200

1

99.3

3.8

30

4.31

0.004

12.42

0.0

99.78

0.86

45

4.59

0.077

15.63

63.7

96.71

1.78

54

3.08

0.123

34.87

69.8

95.9

0.03

55

4.37

0.016

200

0.5

99.4

13.34

56

3.73

0.065

29.53

20.1

97.9

na

Compound

Structure
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Table 3-4.

Compound

57

(Continued).

Structure

H. p.
ClogP
IC50
[μg/mL]

4.18

0.034
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Cytotox
Human
FaDu
Solubility Plasma
Cell
Binding
[μM]
[μg/mL]
(%)

24.82

2.4

98.1

Mouse
Microsomal
Stability t1/2
[hr]

na

pharmacokinetic properties revealed compound 56, which demonstrates an improved
solubility and is less bound to plasma protein. The removal of the sulfur greatly improves
the solubility and the plasma protein binding. Para-fluoro substitution at the 6-phenyl
group significantly improves the microsomal stability of the series. The
pyrrolopyrimidine scaffold is a promising core in the optimization of the ADME
properties, to discover a candidate for in vivo efficacy studies in the H. pylori murine
model.
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CHAPTER 4.

CONCLUSION

H. pylori is the causative agent of gastritis, peptic ulcers and gastric cancer. The
recommended therapy for H. pylori infections is the triple therapy which consists of a
PPI, and two antibiotics including clarithromycin and amoxicillin. The rate of successful
treatment with the triple therapy has dropped below 80%, due to the global rise of
resistance against these antibiotics. The World Health Organization lists H. pylori as a
high priority drug-resistant bacterium. A narrow-spectrum drug is needed to address the
drug resistance challenge and preserve these broad-spectrum antibiotics for the treatment
of other types of infections. Advances in whole genome sequencing provide an
opportunity to discovery new chemical matter. Recent transposon mutagenesis studies
have revealed H. pylori specific genes that enable the pathogen to grow in the stomach.
The existence of these genes suggests that there are novel and unique targets that can
explored for the development of novel therapies against H. pylori infections. Phenotypic
screening for selective compounds against H. pylori is a promising approach to unveil
these targets.
In an effort to discover a new chemical matter, we conducted a high-throughput
screen of 219,197 compounds. Positive hits were counter-screened against a number of
gut commensals, to eliminate promiscuous compounds. Two thienopyrimidines emerged
from this screen and were explored through the synthesis of 29 analogs and the structure
activity relationship (SAR) studies that merged elements from both hits. The SAR
revealed several potent compounds, in low μg/mL-range of activity, including compound
25 (H.p. IC50: 0.006 μg/mL). Mode of action studies that involved the generation of
mutants, revealed NuoD, a subunit of H. pylori’s respiratory Complex 1, as the putative
target of the thienopyrimidine. Complex I is an enzyme that catalyzes the first step of
oxidative phosphorylation.
Targeting oxidative phosphorylation has been proven to be beneficial in the clinic,
as exemplified by metformin, a drug that is used for the treatment of diabetes. The
inhibition of oxidative phosphorylation is becoming an important approach in the
development of therapies for the treatment of AML and solid tumors. Additionally, NuoD
has been found to be essential for H. pylori but not for most of other bacteria including E.
coli. These realizations suggest that the thienopyrimidines are a promising series of
compounds, worth further optimization to fulfill the eradication of H. pylori in the in vivo
murine model. The lead thienopyrimidine compound 25 eradicates H. pylori in the ex
vivo model but lacks in vivo efficacy, suggesting the optimization of pharmacokinetic
properties of the lead compound 25 is required.
To address the limitations of 25, we have synthesized 16 additional compounds.
At 50 mg/kg, compound 25 shows good exposure (AUC: 31907.71 hr*ng/mL) with a
high volume of distribution (Vss: 6.28 L/Kg), suggesting that 25 (Clogp: 4.23) is too
lipophilic and is being trapped in fatty tissues. 25 also shows poor solubility (Sol: 0.1
μM) and high plasma protein binding (HPPB: 99.3 %), suggesting not enough of free
drug concentration is able to reach the site of infection, in the mucus layer of the
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stomach. New compounds include amine derivatives of 25 and other lead compounds
such as 30 and 45, to improve the solubility of the series. Scaffold hopping exercise that
aimed to remove the lipophilic sulfur atom, revealed pyrrolopyrimidine and quinazoline
scaffolds. The pyrrolopyrimidine analog 56 is less lipophilic (ClogP: 3.73), demonstrates
an improved solubility (Sol: 20.1 μM) and is less bound to plasma protein (HPPB: 97.9
%) compared to lead compound 25. Compound 56 is a promising compound, in the lead
optimization efforts toward the in vivo proof of concept studies in the H. pylori murine
model. 6-pyridinyl substituted derivative of pyrrolopyrimidine 56 will likely lead to
improved solubility and decreased plasma protein binding. Fluorination of the 6-aryl ring
will prolong the half-life of drug in vivo. Substitution of the (R)-3-amino-3-(4methoxyphenyl) propanol motif, identified with compound 45, at the 4-position of the
pyrrolopyrimidine core could lead to a series with improved solubility and low plasma
protein binding.
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APPENDIX.
Table A-1.
Inhibition profile of thienopyrimidines against H. pylori ATCC 43504
strain, SS1 strain and SS1 mutant strain.

Compound

H. pylori IC50 (μg/ml)
ATCC
SS1
SS1
43504
nuoD
Ratio
Strain
Strain
A402P

Cytotoxicity
IC50(μg/ml)
HepG2 Cells

1

0.44
± 0.19

0.46
± 0.07

15.42
± 11.51

33.58

42.68
± 14.00

8

>10
± 0.00

1.85
± 1.48

15.48
± 12.61

8.38

36.52
± 9.44

9

1.53
± 0.43

0.55
± 0.22

20.19
± 12.39

36.96

81.55
± 26.07

10

0.01
± 0.007

0.05
± 0.09

3.04
± 3.38

55.00

46.83
± 4.08

11

0.34
± 0.24

0.13
± 0.07

5.50
± 2.79

43.46

51.05
± 4.96

12

1.55
± 0.21

0.98
± 0.71

5.59
± 2.92

5.73

103.67
± 23.29

13

0.05
± 0.007

0.01
± 0.007

3.35
± 3.28

267.39

96.49
± 9.64

14

0.41
± 0.24

0.16
± 0.09

5.42
± 2.69

34.81

42.64
± 10.81

15

0.72
± 0.33

0.18
± 0.12

11.04
± 13.92

61.18

>200
± 2.27

16

0.03
± 0.006

0.02
± 0.00

2.59
± 3.07

162.38

43.56
± 5.42

17

0.31
± 0.21

0.08
± 0.05

4.89
± 3.43

55.68

26.77
± 0.61

18

1.09
± 0.12

0.24
± 0.05

14.28
± 11.30

58.40

33.58
± 9.96
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Table A-1.

(Continued).
H. pylori IC50 (μg/ml)

Compound

ATCC
43504
Strain

SS1
Strain

SS1
nuoD
A402P

Ratio

Cytotoxicity
IC50(μg/ml)
HepG2
Cells

19

0.08
± 0.06

0.02
± 0.002

0.29
± 0.33

17.68

>200
± 0.00

20

0.03
± 0.004

0.22
± 0.17

3.34
± 3.41

15.36

135.01
± 40.25

21

0.92
± 0.30

0.48
± 0.32

1.27
± 1.87

2.63

29.26
± 3.34

22

1.97
± 0.71

1.08
± 0.47

4.4
± 2.98

4.07

31.86
± 3.38

23

0.57
± 0.08

0.24
± 0.17

5.48
± 2.83

23.13

12.45
± 1.70

24

0.06
± 0.03

0.09
± 0.03

3.53
± 0.29

41.12

6.51
± 11.515

25

0.004
± 0.000

0.004
± 0.000

0.1
± 0.09

18.41

>200
± 0.00

26

0.004
± 0.002

0.004
± 0.000

0.06
± 0.05

15.59

18.76
± 3.64

27

0.02
± 0.003

0.05
± 0.045

1.75
± 0.71

45.55

28.22
± 0.54

28

0.02
± 0.003

0.01
± 0.007

0.44
± 0.31

39.11

<6.25
± 0.00
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Table A-1.

Compound

(Continued).
H. pylori IC50 (μg/ml)
ATCC
SS1
SS1
43504
nuoD
Ratio
Strain
Strain
A402P

Cytotoxicity
IC50(μg/ml)
HepG2 Cells

29

0.009
± 0.003

0.004
± 0.001

0.22
± 0.17

58.03

7.59
± 1.74

30

0.007
± 0.002

0.004
± 0.000

0.19
± 0.16

49.01

10.71
± 2.94

31

1.19
± 0.27

0.54
± 0.36

6.92
± 1.075

12.87

<6.25
± 0.00
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Table A-2.
Inhibition profile of thienopyrimidines with modifications at the 5 and
6 positions against H. pylori ATCC 43504 strain, SS1 strain and SS1 mutant strain.

H. pylori IC50 (μg/ml)

Compound

R1

R2

37

CH3

CH3

38

CH3

39

CH3

40

H

Table A-3.

ATCC
43504
Strain
1.77
± 0.05
0.12
±
0.007
1.51
± 1.49
1.51
± 0.27

0.25
± 0.18

SS1
nuoD
A402P
5.05
± 3.26

0.02
± 0.001

3.71
± 2.87

10.24
± 13.58
0.215
± 0.16

10.51
± 12.95
0.44
± 0.35

SS1
Strain

19.89
222.93
1.03
2.06

20.64
± 6.00
32.93
± 1.92
27.86
± 9.41

ADME of the lead compound 25.

Compound

MW

ClogP

Solubility
[μM]

25

377

4.23

1
± 0.2

a The

Ratio

Cytotoxicity
IC50(μg/ml)
HepG2 Cells
<6.25
± 0.00

PAMPAa
Avg Pe
(10-6
cm/s)

Mouse
Plasma
Binding
(%)

Microsomal
Stability
(Mouse)
t1/2 [hr]

239.5
± 180.5

99.3
± 0.1

3.8
± 0.37

PAMPA assay was carried out at physiological (pH = 7.4).

81

Table A-4.
Evaluation of in vivo pharmacokinetic properties of the lead
compound 25.
Compound Route
25

i.p.
PO

Dose
Tmax
Cmax
AUClast
T1/2
CL
Vss
[mg/kg] (hr) (ng/mL) (hr*ng/mL) (hr) (mL/min/kg) (L/kg)
50
2.00 2550.25
31 907.71 2.79
26.05
6.28
10
0.25 589.84
674.42
1.52
-

Figure A-1. In vivo efficacy of compound 25 in the H. pylori infected mouse model.
C57BL16 mice were infected with a H. pylori SS1 strain suspension. Then, mice were
treated with metronidazole as control, and the following doses of compound 25, twice per
day: 50 mg/kg (OG), 50 mg/kg (IP) and 25 mg/kg (IP).
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